Citation: Durkin, L.A.; Childs, C.E.; Calder, P.C. Omega-3 Polyunsaturated Fatty Acids and the Intestinal Epithelium—A Review. Foods 2021, 10, 199. https://doi.org/10.3390/foods10010199

Received: 7 December 2020
Accepted: 11 January 2021
Published: 19 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

In humans, the gut (intestinal) barrier is the largest interface separating the internal and external environments. The main cells forming the barrier are epithelial cells, although other cell types are also present. Intestinal epithelial cells (enterocytes) have a vital role in uptake of nutrients and water, in protecting internal systems from noxious environmental stressors and in regulating responses to both harmful and harmless external stimuli. Epithelial cells must respond to commensal and pathogenic bacteria, co-exist and interact with intestinal immune cells, and deal with nutrients and other substances from the diet [1]. The function and integrity of the epithelial barrier are governed by the tightly regulated axis between the epithelial cells, the microbiota, mucus and anti-microbial peptides, and immune cells. Disruption of intestinal epithelium function leads to increased permeability and loss of immunological control, which is believed to contribute to a number of pathological states and diseases, including inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), coeliac disease and irritable bowel syndrome [2]. Communication between epithelial cells, the gut microbiota, and intestinal immune cells is through both...
direct cell–cell contact and through the production of chemical mediators, including both small metabolites such as short-chain fatty acids (SCFAs) and larger immune mediators such as cytokines and chemokines [3,4].

The gut epithelium interacts with a range of nutrients and other components from the diet, which can both affect barrier function and be absorbed across the barrier into the bloodstream. The influence of diet-derived substances on gut epithelial function including barrier integrity is likely to be important. Excessive inflammation or oxidative stress can disrupt barrier function. Vitamins (including vitamins C, D3, and E) [5,6], phytochemicals (including polyphenols and flavonoids) [7], SCFAs [8], and polyunsaturated fatty acids (PUFAs) [9] are known to have anti-oxidant and anti-inflammatory effects on a range of cell types. Omega-3 (ω-3) PUFAs have been widely studied in the context of inflammation [9–12], with anti-inflammatory effects being described and benefits related to these being reported in several disease states, including cardiovascular disease [13], rheumatoid arthritis [14], and inflammatory bowel diseases [15]. The two main bioactive ω-3 PUFAs are eicosapentaenoic acid (EPA; 20:5ω-3) and docosahexaenoic acid (DHA; 22:6ω-3), although roles for docosapentaenoic acid (DPA; 22:5ω-3) are now emerging. These fatty acids can be consumed directly in high amounts by eating oily fish, such as salmon, mackerel and sardines, or by taking fish oil supplements. Additionally, the plant-derived ω-3 PUFA, alpha-linolenic acid (ALA; 18:3ω-3), found abundantly in flaxseeds and walnuts, and in rapeseed (sometimes called canola) and soybean oils, can be consumed as a precursor for EPA and DHA synthesis in humans, as shown in Figure 1, although humans have a relatively low conversion rate of ALA to EPA and on to DHA [16].

The mechanisms by which EPA and DHA exert anti-inflammatory effects have been described elsewhere in detail [9–12] and include partial replacement of arachidonic acid (AA; 20:4ω-6) in cellular phospholipids, inhibition of several inflammatory signalling pathways, and activation of peroxisome proliferator-activated receptor (PPAR)-γ and G-protein coupled receptor (GPR) 120, which subsequently inhibit the action of the pro-inflammatory transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [17]. These anti-inflammatory effects of ω-3 PUFAs have been mostly studied in classic inflammatory cells such as monocytes, macrophages and neutrophils and also in endothelial cells and result in decreased cellular activation and reduced production of inflammatory cytokines, chemokines and lipid mediators and increased production of pro-resolving lipid mediators [9–12]. Several enzymes, known to produce mediators of inflammation such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), are also known to be modulated by ω-3 PUFAs. Despite this extensive research, effects of ω-3 PUFAs on intestinal epithelial cells are less well recognised, even though controlling inflammation at the level of the intestinal epithelium is clearly important. This review aims to bring together the relevant literature assessing the role of ω-3 PUFAs, including ALA, EPA, DPA and DHA, on the function of intestinal epithelial cells with an emphasis on inflammation.
Figure 1. Metabolic conversion pathway from the essential ω-3 PUFA, ALA, to longer-chain ω-3 PUFAs, EPA, DPA and DHA. Conversion data are from [18].

2. Models for Studying the Intestinal Epithelium

Directly assessing the function of the human gut epithelium in vivo is a challenge, as assessing intestinal barrier morphology, integrity and function by biopsy or endoscopy is both time consuming and invasive. Alternative indirect in vivo assessments of epithelial barrier function include permeability assays using large or small inert sugars as markers for intestinal absorption, and measuring bacterial products, such as lipopolysaccharide (LPS; also known as endotoxin), or markers of enterocyte functionality, such as citrulline and intestinal fatty acid-binding protein, within serum or plasma [19]. These less invasive approaches give insight into overall gut barrier functionality, but they cannot identify the location or cause of any differences observed, and therefore the use of complementary in vivo and in vitro techniques allows for more insight into the mechanisms of intestinal
epithelium function in health and disease and for the study of the effect of stressors and modulators.

Cellular models of the intestinal epithelium provide a useful tool to investigate the potential roles of nutrients, such as ω-3 PUFAs, in vitro. Although the complexity of the intestinal barrier is difficult to replicate in vitro, multiple models are available to study intestinal epithelial cells. Human colorectal tumour-derived cell lines, such as Caco-2, T84, and HT-29, as well as rodent-derived cell lines, such as IEC-6 and IEC-18, provide replicable and high-throughput models of the intestinal epithelium [20,21], whilst organ-on-a-chip cultures have begun to replicate more in vivo-like epithelial properties and behaviours [22]. These models allow for in vitro assessment of a multitude of outcomes, including changes to membrane composition, permeability, transport processes, inflammatory mediator production, receptors and signalling pathways, the cell cycle and apoptosis.

3. ω-3 PUFAs and Intestinal Epithelial Fatty Acid Composition

One central mechanism linked to the regulatory properties of ω-3 PUFAs is alteration and modulation of membrane fatty acid composition [9–12]. This has been demonstrated in many cell types, including in intestinal epithelial cells (see Table 1). EPA supplementation of cultured Caco-2 cells increased their membrane content of EPA [23], and 96 h supplementation with EPA and DHA increased the respective amounts of those fatty acids in Caco-2 cells [24]. Further investigation of the incorporation of EPA, as well as of DHA and ALA, in Caco-2 and T84 cells, indicated that EPA accumulates in the phospholipid fraction, unlike DHA and ALA which accumulate in the neutral lipid pool [25]. This suggests differential metabolism and handling of ω-3 PUFAs in these cells and, further, that EPA and DHA could have different functional effects in these cells. However, in separate studies, ALA, EPA, and DHA all accumulated in T84 cell phospholipids [26], whilst EPA and DHA increased ω-3 PUFA content in T84 cell lipid rafts [27], after 48 h supplementation. It is not clear why different studies have suggested different fates of ω-PUFAs in these cells, but this might relate to methodological differences between the studies.

In addition to simply incorporating the ω-3 PUFA provided in the culture medium, bioconversion of exogenous ω-3 PUFAs can also occur in epithelial cells. This has been shown in both Caco-2 and T84 cells supplemented with 30 µM of each respective fatty acid for 7 days (summarised in Table 2). Supplementation of T84 cells with ALA significantly increased ALA and eicosatrienoic (ETE; 20:3ω-3) contents compared to untreated control cells [25]. ALA and ETE contents were also increased in ALA supplemented Caco-2 cells compared to controls [25]. The appearance of ETE suggests that elongation of ALA may be preferred in these cells rather than ALA desaturation catalysed by the FADS2 gene product which is shown in Figure 1. Additionally, EPA was significantly increased in ALA-treated Caco-2 cells, suggesting that these cells have an intact pathway of conversion of ALA to EPA. This may use the direct pathway shown in Figure 1 or, if ETE is involved, then ETE can be converted to eicosatetraenoic acid (ETA; 20:4ω-3) by delta-8 desaturation most likely catalysed by an alternative activity of the FADS2 gene product delta-6 desaturase (Figure 1). EPA supplementation significantly increased EPA content in both Caco-2 and T84 cells compared to untreated control cells [25]. EPA supplementation also significantly increased DPA content compared to controls, although the increase was much greater in Caco-2 cells compared to T84 cells [25,28]. An increase in EPA and DPA content was also associated with decreased cellular content of trans-vaccenic acid, cis-9, trans-11-conjugated linoleic acid, and oleic acid in both T84 and Caco-2 cell lines [28]. Arachidonic acid (AA) decreased in EPA-treated Caco-2 and T84 cells [23], although this was not statistically significant, whilst DHA treatment decreased AA only in the T84 cell line [25]. DHA supplementation greatly increased DHA content in both Caco-2 and T84 cells [25]. In Caco-2 cells DHA significantly increased EPA content [25], indicating the presence of a so-called retroconversion step. However, this was not seen in T84 cells where DHA supplementation decreased DPA content [25].
### Table 1. Effects of ω-3 PUFAs on fatty acid composition in intestinal cell models or tissue.

| Reference       | Model Used       | Condition                        | ω-3 PUFA(s) Used | Concentration or Dose Used | Duration                  | Change in Fatty Acid Composition |
|-----------------|------------------|----------------------------------|------------------|----------------------------|---------------------------|----------------------------------|
|                 | Cell line models |                                   |                  |                            |                           |                                  |
|                 |                   |                                   |                  |                            |                           |                                  |
| Rosella et al. [23] | Caco-2 cells     | Non-stimulated                   | EPA              | 100 µg/mL                  | 24 h                      | ↑ Membrane EPA content           |
| Renaville et al. [28] | T84/Caco-2 cells| Non-stimulated                   | EPA              | 30 or 300 µM               | 3 h or 3 h and 7 days     | ↑ Cellular EPA content           
|                  |                  |                                  |                  |                            |                           | ↑ Cellular DPA content           
|                  |                  |                                  |                  |                            |                           | ↓ Cellular trans-vaccenic acid content  
|                  |                  |                                  |                  |                            |                           | ↓ Cellular cis-9, trans-11-conjugated linoleic acid  
|                  |                  |                                  |                  |                            |                           | ↓ Cellular oleic acid content    |
| Willemsen et al. [26] | T84 cells        | IL-4-induced inflammation        | ALA              | 10 or 100 µM               | 96 h                      | ↑ Phospholipid ALA content       |
|                  |                  |                                  | EPA              |                            |                           |                                  |
|                  |                  |                                  | DHA              |                            |                           |                                  |
| Li et al. [27]   | T84 cells        | TNF-α- and IFN-γ-induced inflammation | EPA        | 25–75 µM                  | 48 h                      | ↑ Lipid raft EPA content         |
|                  |                  |                                  | DHA              |                            |                           |                                  |
| Xiao et al. [24] | Caco-2 cells     | Heat stress                      | EPA              | 50 µM                      | 96 h                      | ↑ Membrane EPA content           |
| Beguin et al. [25] | T84 cells        | Non-stimulated                   | ALA              | 30 µM                      | 7 days                    | ↑ Cellular ALA content           
|                  |                  |                                  | EPA              |                            |                           | ↑ Cellular ETE content           |
|                  |                  |                                  | DHA              |                            |                           |                                  |
|                  | Caco-2 cells     | Non-stimulated                   | ALA              |                            |                           |                                  |
|                  |                  |                                  | EPA              |                            |                           |                                  |
|                  |                  |                                  | DHA              |                            |                           |                                  |
### Table 1. Cont.

| Reference          | Model Used       | Condition                          | ω-3 PUFA(s) Used | Concentration or Dose Used                                   | Duration | Change in Fatty Acid Composition                      |
|--------------------|------------------|------------------------------------|------------------|------------------------------------------------------------|----------|--------------------------------------------------------|
| **Rodent models**  |                  |                                    |                  |                                                            |          |                                                        |
| Nieto et al. [29]  | Rats             | TNBS colitis                       | Fish oil         | EPA: 4.16% of dietary fatty acids                           | 7 or 14 days | ↑ Colonic tissue EPA content ↑ Colonic tissue DHA content |
|                    |                  |                                    |                  | DHA: 3.01% of dietary fatty acids                           |          |                                                        |
| Bosco et al. [30]  | Rag2−/− immunodeficient mice | Adoptive transfer of naive T-cell-induced colitis | Fish oil | EPA: 3.37 g/100 g diet DHA: 2.10 g/100 g diet | 8 weeks | ↑ Colonic free EPA (7.2-fold) ↑ Colonic free DHA (2.2-fold) ↓ Colonic free arachidonic acid |
| Brahmbhatt et al. [31] | Male Sprague–Dawley rats | Intestinal reperfusion and ischaemia | Fish oil | EPA: 3.00% of dietary fatty acids DHA: 1.98% of dietary fatty acids | 21 days | ↑ Small intestine tissue EPA content ↑ Small intestine tissue DHA content |
| Reifen et al. [32] | Male Wistar rats | TNBS- or DSS-induced colitis | Fish oil | Fish oil: 5% by weight of total diet (EPA: 11.7% of total fatty acids DHA: 15.7% of total fatty acids) | 21 days | ↑ Colonic tissue EPA content ↑ Colonic tissue DHA content |
| Xiao et al. [33]   | Male Wistar rats | Heatstroke                         | EPA              | 1 g/kg body weight per day by gavage                        | 21 days | ↑ Ileal phospholipid EPA content                       |
|                    |                  |                                    |                  | DHA                                                        |          | ↑ Ileal phospholipid DHA content                       |
| **Human studies**  |                  |                                    |                  |                                                            |          |                                                        |
| Hillier et al. [34]| Human            | Inflammatory bowel disease         | Fish oil         | Fish oil: 18 g/day (3.3 g EPA + 2.2 g DHA/day)              | 12 weeks | ↑ Colonic mucosa EPA content ↑ Colonic mucosa DHA content ↓ Colonic mucosa AA content |
| Hawthorne et al. [35]| Human            | Inflammatory bowel disease         | Fish oil         | Fish oil: 20 mL/day (4 g EPA + 1.2 g DHA/day)               | 1 year  | ↑ Rectal mucosa EPA content                           |

Abbreviations used: ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DSS, dextran sodium sulphate; EPA, eicosapentaenoic acid; ETE, eicosatrienoic acid; IFN, interferon; IL, interleukin; PUFA, polyunsaturated fatty acid; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumour necrosis factor.
Table 2. Fatty acid content changes in gut epithelial cell lines (T84 and Caco-2) after 7 days of supplementation with ALA, EPA or DHA. Fatty acid content is given as mean picomoles of fatty acid per microgram of protein ± standard error, () indicate fold change compared to control. * Significant differences between treatment and control. Data are from [25].

| Cell line | Control (No Added ω-3 PUFA) | ALA Treatment | EPA Treatment | DHA Treatment |
|-----------|-----------------------------|---------------|---------------|---------------|
|           | T84 | Caco-2 | T84 | Caco-2 | T84 | Caco-2 | T84 | Caco-2 |
| ALA       | 4.5 ± 1.2 | 30.1 ± 6.9 | 144.5 ± 0.6 * (32.1) | 414.9 ± 40.1 * (13.8) | 1.4 ± 0.6 (−0.3) | 31.5 ± 4.7 (1.0) | 2.3 ± 1.1 (−0.5) | 41.3 ± 4.2 (1.4) |
| ETE       | 0.7 ± 0.4 | 7.0 ± 0.8 | 3.9 ± 0.3 * (5.6) | 83.1 ± 9.3 * (11.9) | 0.3 ± 0.3 (−0.4) | 7.5 ± 0.8 (1.1) | Not detected | 7.5 ± 0.8 (1.1) |
| EPA       | 9.5 ± 1.6 | 15.4 ± 1.9 | 8.9 ± 10.2 (−0.9) | 20.7 ± 2.3 * (1.3) | 130.8 ± 11.1 * (13.8) | 257.6 ± 37.2 * (16.7) | 17.0 ± 5.9 (1.8) | 32.3 ± 4.4 * (2.1) |
| n-3 DPA   | 5.7 ± 1.2 | 19.9 ± 2.0 | 4.5 ± 1.3 (−0.8) | 21.6 ± 2.1 (1.1) | 10.6 ± 1.4 * (1.9) | 157.4 ± 23.2 * (7.9) | 1.1 ± 0.5 * (−0.2) | 24.9 ± 3.3 (1.3) |
| DHA       | 11.8 ± 1.8 | 37.2 ± 4.1 | 9.8 ± 0.7 (−0.8) | 40.8 ± 3.9 (1.1) | 7.4 ± 0.7 (−0.6) | 33.9 ± 4.9 (−0.9) | 114.5 * ± 32.4 (9.7) | 478.3 ± 58.7 * (12.9) |
| Total ω-3 PUFAs | 32.3 ± 6.3 | 72.5 ± 8.1 | 171.6 ± 13.0 * (5.3) | 581.2 ± 8.3 * (8.0) | 150.7 ± 14.2 * (4.7) | 448.9 ± 65.3 * (6.2) | 135.0 ± 39.9 * (4.2) | 535.5 ± 66.4 * (7.4) |

Abbreviations used: ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; ETE, eicosatrienoic acid.
Changes to epithelial cell fatty acid composition after ω-3 PUFA treatment have also been reported in vivo (Table 1). Due to the complexity of obtaining intestinal biopsies, in vivo evidence from human studies on changes to fatty acid composition of epithelial cells is limited. Hawthorne et al. showed that in patients with ulcerative colitis and after 1 year of fish oil supplementation, rectal mucosa EPA content increased, but mucosal DHA content was not significantly affected [35]. However, basal levels of DHA were higher in rectal mucosa compared to EPA (1.4% vs. 0.4% total fatty acids, respectively) and approximately 4-fold more EPA was consumed compared to DHA, across the trial period. In a separate human study, 12 week fish oil supplementation in patients with inflammatory bowel disease increased colonic mucosal concentrations of EPA and DHA, which coincided with a decrease in colonic mucosal AA content [34].

Rodent models have been used to assess changes in mucosal and epithelial fatty acid compositions after dietary provision of ω-3 PUFAs (Table 1). Male Wistar rats with diets supplemented with EPA or DHA for 21 days showed increased epithelial cell phospholipid concentrations of each respective PUFA [33]. Male Sprague–Dawley rats consuming a diet containing EPA and DHA, over a similar 3 week supplementation period, also had significantly increased EPA and DHA content in small intestine tissue [31]. Additionally, rats fed a diet containing fish oil with moderate concentrations of EPA and DHA in a 2,4,6-trinitrobenzene sulphonic acid (TNBS) colitis model showed significant increases in EPA and DHA content in colonic tissue [29]. Fish oil supplementation, making up 5% of the diet of male Wistar rats for 3 weeks, was again shown to significantly increase EPA and DHA content in colonic tissue after TNBS or dextran sodium sulphate (DSS)-induced colitis treatment [32]. Rag2−/− immunodeficient mice supplemented for 8 weeks with fish oil had increased free concentrations of EPA and DHA (EPA > DHA) and decreased free concentrations of AA in colonic tissue [30]. Thus, it is clear that when exposure to EPA and DHA is increased (in cell culture or in the diet of experimental animals or humans), intestinal epithelial cells incorporate those fatty acids. Often this incorporation has been reported to be at the expense of the ω-6 PUFA, AA.

4. ω-3 PUFAs and Intestinal Epithelial Morphology

Improvements in gut epithelial function attributed to ω-3 PUFAs are exemplified by improved histological outcomes seen in several in vivo models. Although improvements have been seen in many studies, there are also reports in which ω-3 PUFA supplementation has little or no effect on gut morphology (summarised in Table 3).

Transgenic mice capable of endogenously synthesising ω-3 PUFAs had increased concentrations of EPA, DPA, and DHA in intestinal epithelial cells, and when exposed to DSS to induce colitis, had improved histological outcomes, including increased colon length, decreased severity and thickness of inflammatory infiltrate, and decreased epithelial damage [36]. In this transgenic model, ω-3 PUFAs are generated endogenously, but many more studies have used exogenous ω-3 PUFAs as a potential preventative or therapeutic strategy in a range of inflammatory conditions of the gut.
Table 3. Effects of ω-3 PUFAs on intestinal histology in rodent models.

| Reference          | Model Used                | Condition                 | ω-3 PUFA(s) Used                               | Dose Used                           | Duration   | Histological Changes                                                                 |
|--------------------|---------------------------|---------------------------|-----------------------------------------------|-------------------------------------|------------|--------------------------------------------------------------------------------------|
| Vilaseca et al. [37]| Male Sprague–Dawley rats | Chronic TNBS colitis      | Cod liver digest (providing EPA and DHA)      | EPA: 5.95 mg/g diet DHA 6.91 mg/g diet | 50 days    | Decreased macroscopic damage (after day 20) Absence of inflammation and ulcerations (day 50) |
| Empey et al. [38]  | Male Sprague–Dawley rats | Acetic acid-induced colitis | EPA-enriched fish oil                         | EPA-enriched fish oil: 10% by weight of total diet | 6 weeks    | Improved histology and less macroscopic injury                                      |
| Shoda et al. [39]  | Rats                      | TNBS colitis              | Fish oil                                      | Fish oil: 2% by weight of total diet  | Not given  | Reduced ulcer severity (correlated with decreased plasma LTB₄)                       |
|                    |                           |                           | ALA-rich perilla oil                          | Perilla oil: 2% by weight of total diet |            | Decreased colonic weight (correlated with decreased plasma LTB₄; ALA > fish oil)     |
| Yuceyar et al. [40]| Male Wistar albino rats  | TNBS colitis              | Fish oil                                      | EPA: 14.4 mg/g diet DHA: 11.6 mg/g diet | 6 weeks (diet) | Improved pathology (decreased number of lesions)                                      |
|                    |                           |                           |                                                |                                     | 14 days (daily enema) | No effect on macroscopic parameters No effect on pathology                            |
| Caplan et al. [41] | Neonatal Sprague–Dawley rats | Necrotising enterocolitis | DHA                                           | 23 mg/100 mL formula               | 96 h       | Improved histological necrotising enterocolitis outcomes                             |
| Andoh et al. [42]  | Male Sprague–Dawley rats | TNBS colitis              | ω-3 PUFA-rich liquid diet (providing ALA)     | 150 mg/100 kcal                    | 12 days (followed by 2 days starvation) | Reduced inflammatory damage score                                                      |
| Hudert et al. [36] | Transgenic fat-1 mice     | DSS colitis               | -                                             | Mice have higher colonic EPA, DPA and DHA than controls | -          | Increased colon length Decreased severity and thickness of inflammatory infiltrate Decreased epithelial damage |
| Lu et al. [43]     | Neonatal Sprague–Dawley rats | Necrotising enterocolitis | DHA                                           | 0.5% of total fatty acids in formula | 72 h       | Improved histology                                                                   |
| Reference          | Model Used                | Condition          | ω-3 PUFA(s) Used | Dose Used                                 | Duration | Histological Changes                                                                 |
|--------------------|---------------------------|--------------------|------------------|-------------------------------------------|----------|--------------------------------------------------------------------------------------|
| Hassan et al. [44] | Male Sprague–Dawley rats | TNBS colitis       | ALA              | 28.8% of total fatty acids in formula     | 14 days  | Decreased macroscopic lesions                                                        |
|                    |                           |                    |                  |                                           |          | Less neutrophil infiltration                                                           |
|                    |                           |                    |                  |                                           |          | No effect on mucosal wall thickness                                                    |
|                    |                           |                    |                  |                                           |          | No effect on overall inflammatory score                                               |
| Bosco et al. [30]  | Rag2−/− immunodeficient mice | Adoptive transfer of naïve T-cell-induced colitis | Fish oil       | EPA: 3.37 g/100 g diet                    | 8 weeks  | No effect on macroscopic parameters of colitis                                        |
| Li et al. [45]     | Male rats                 | Haemorrhagic shock | Fish oil         | Fish oil: 0.2 g/kg body weight            | Single intravenous treatment | Less mucosal damage                                                                    |
|                    |                           |                    |                  |                                           |          | Improved tight junction morphology                                                    |
| Reifen et al. [32] | Male Wistar rats          | TNBS- or DSS-induced colitis | Sage oil (providing ALA) | Oils: 5% by weight of diet               | 21 days  | No effect on DSS or TNBS colitis-induced histological changes                          |
|                    |                           |                    |                  |                                           |          | Increased mucosal inflammation (DSS colitis only)                                     |
|                    |                           |                    |                  |                                           |          | Fish oil                                                                               |
| Zhao et al. [46]   | Mice                      | IL-10 deficiency   | DHA              | 35.5 mg/kg body weight per day intragastrically | 14 days  | Improved histological inflammation score                                              |
| Chien et al. [47]  | Male Wistar rats          | Chronic ethanol exposure | Fish oil       | 7.1 or 16.2 g/kg diet                    | 8 weeks  | No effect on epithelial histological damage                                           |
| Yao et al. [48]    | Male Sprague–Dawley rats | TNBS colitis       | ω-3 PUFAs (source not specified but presumed to be fish oil) | 20 mg/kg body weight per day intragastrically | 60 days  | Decreased disease activity index score                                                |
|                    |                           |                    |                  |                                           |          | Decreased colonic macroscopic damage index score (decreased ulceration)               |
|                    |                           |                    |                  |                                           |          | Decreased tissue damage index score (reduced thickening and leukocyte infiltration)    |
Table 3. Cont.

| Reference                  | Model Used            | Condition                     | ω-3 PUFA(s) Used                                      | Dose Used                      | Duration | Histological Changes |
|----------------------------|-----------------------|-------------------------------|------------------------------------------------------|--------------------------------|----------|----------------------|
| Charpentier et al. [49]    | Young male Sprague–Dawley rats | TNBS colitis                  | ω-3 PUFAs (source not specified but presumed to be fish oil) | 6.1 g/kg of diet               | 28 days  | No effect on colonic weight to length ratio |
| Haddi et al. [50]          | Female BALB/c mice    | β-lactoglobulin-induced inflammation | Fish oil                            | 0.6, 1 or 1.5 mL/kg body weight per day by gavage | 15 days  | Increased villus height | Improved intestinal architecture Improved histological score |
| Tang et al. [51]           | Female Sprague–Dawley rats | Peritoneal dialysis           | ω-3 PUFAs (source not specified)                  | 0.5 or 1.5 g/kg body wt per day intragastrically | 28 days  | Increased ileal villus length | Increased crypt depth/ileal villus length ratio |
| Zheng et al. [52]          | Male C57 mice         | DSS colitis                   | DPA                                   | 300 mg/kg body weight per day by gavage               | 28 days  | Attenuated body weight decrease | Decreased disease activity index score | Improved gross morphology and pathological inflammatory score | Attenuated inflammatory infiltration Attenuated colon shortening |

Abbreviations used: ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DSS, dextran sodium sulphate; EPA, eicosapentaenoic acid; LT, leukotriene; PUFA, polyunsaturated fatty acid; TNBS, 2,4,6-trinitrobenzenesulfonic acid.
Single-dose DHA treatment has been shown to reduce the incidence of necrotising enterocolitis in neonatal Sprague–Dawley rats, as indicated by lower numbers of villous necroses [41,43]. Moreover, prolonged DHA exposure (14 days) in the IL-10-deficiency-induced murine colitis model reduced colonic inflammation and inflammatory scores and inflammatory cell infiltration into the intestinal mucosa, and partially restored goblet and glandular architecture [46]. In a model of DSS-induced colitis, EPA also had a protective effect on disease severity and gut morphology, including attenuated colon shortening, decreased inflammatory infiltration into colonic tissue, and attenuated body weight loss, as well as overall decreases in pathology and gross morphological injury scores [52]. Food oil, containing both EPA and DHA, has also exhibited protective effects on gut histology in other models, including reducing mucosal damage and preventing tight junction protein redistribution in a rat haemorrhagic shock model [45], as well as increasing villous length and crypt depth/villosus length ratio in a female Sprague–Dawley rat model of peritoneal dialysis [51]. Fish oil also significantly increased villous height and improved histological architecture scores in β-lactoglobulin-treated female BALB/c mice, as well as preventing changes to short current circuit and tissue conductance in jejunal tissue [50]. EPA-enriched fish oil, given over a 6 week period, also reduced macroscopic inflammation parameters in an acetic acid-induced colitis model [38]. However, in chronic ethanol-exposed male Wistar rats, fish oil had no effect on histological epithelial damage [47].

In young male Sprague–Dawley rats, ω-3 PUFAs given over 28 days had no effect on TNBS colitis-induced alterations to colon length to weight ratio [49]. This is in accordance with the lack of effect seen in a TNBS-induced colitis model using male Wistar rats supplemented with fish oil [32]. Conversely, in an adult Sprague–Dawley rat model of TNBS colitis, ω-3 PUFA supplementation over 60 days decreased macroscopic parameters of inflammation, including reducing ulcerations, tissue thickening, and inflammatory cell infiltration [48]. Male Sprague–Dawley rats consuming a cod liver digest (rich in ω-3 PUFAs) over 50 days showed decreased macroscopic damage scores and absence of colonic inflammation and ulcerations in chronic TNBS-induced colitis [37]. Short-term (12 days) consumption of a ω-3 PUFA-rich diet also reduced histological inflammation initiated by TNBS [42]. Yuceyar et al. described that the mode of delivery of fish oil can influence its effectiveness in preventing histological changes in TNBS colitis. Fish oil given in the diet, over a 6 week period, was able to attenuate lesion quantity and improved pathological scores in TNBS-induced colitis, whilst the same dose given by daily enema, over a 2 week period, had no effect on macroscopic parameters of inflammation and overall pathology score [40].

In contrast to the many findings of benefit of ω-3 PUFAs described above, Reifen et al. reported that fish oil treatment increased mucosal inflammatory scores in a DSS-induced colitis model using male Wistar rats, while ALA-rich sage oil had no effect on in vivo parameters of inflammation in either TNBS- or DSS-induced colitis [32]. However, Shoda et al. showed protective effects of both fish oil and ALA-rich perilla oil in a model of TNBS-induced colitis. Both treatments altered colitis-induced histological changes, with fish oil reducing ulcer severity and perilla oil reducing the increase in colonic weight [39]. In a Sprague–Dawley rat model of TNBS colitis, ALA reduced macroscopic lesions and neutrophil infiltration, but had no effect on colitis-induced changes to wall thickness and overall inflammatory score [44]. Thus, although there is substantial literature on benefits of ω-3 PUFAs in various models of gut inflammation, there are some contrary findings which might be due to differences between models, age groups, ω-3 PUFA dose, and delivery method of ω-3 PUFAs.

5. ω-3 PUFAs and Intestinal Permeability

Regulated permeability is one of the vital functions of the intestinal epithelium. The structure and function of intercellular junctions, including tight junctions, are integral to maintaining the uptake of nutrients and preventing the translocation of commensal bacteria and their products across the epithelial barrier. Tight junctions consist of extracellular
spanning proteins, occludin and claudin, which interact with adjacent cells at cell–cell contact sites, and anchoring protein, zonula occludens (ZO)-1, which attaches occludin and claudin to the actin cytoskeleton [53], as shown in Figure 2. Adherens junctions are intercellular adhesion structures, responsible for maintaining tissue integrity and control of epithelial cell motility and proliferation [54]. Desmosomes are adhesion sites between adjacent cells, which provide linkage to the intermediate filament cytoskeleton and provide resistance against mechanical stress [55]. Junction adhesion molecule (JAM)-1 is associated with barrier function and tight junction assembly [56]. Disruption of intercellular junctions occurs in response to increased presence of inflammatory cytokines, pathogenic bacteria, or bacterial lipopolysaccharides [53], which induce regulatory proteins, such as myosin light chain kinase (MLCK), leading to tight junction protein degradation or endocytosis [57]. Intercellular junction dysfunction can also be attributed to certain pathological conditions, including inflammatory bowel disease, obesity, and non-alcoholic fatty liver disease [53]. Nutrients from the diet, including amino acids, vitamins A and D, and polyphenols, are known to modulate intercellular junctions, in particular tight junctions [58].

The effects of ω-3 PUFAs on permeability in in vitro and in vivo models are summarised in Table 4. Usami et al. reported that ALA, EPA and DHA all reduced barrier integrity of Caco-2 cell monolayers, indicated by increased fluorescein sulfonic acid permeability and decreased transepithelial electrical resistance [59,60]. These increases in permeability could be associated to a cytotoxic level of ω-3 PUFAs being used, as high levels of EPA increased lactate dehydrogenase (LDH) release into the culture medium, a marker for cytotoxicity, in Caco-2 cell monolayers [59]. In contrast to these findings, EPA and DHA have been shown to improve barrier integrity in many other in vitro studies. In unstimulated Caco-2 cell monolayers, 24 h EPA supplementation reduced permeability of horseradish peroxidase [23]. EPA and DHA were shown to attenuate increases in permeability induced by pro-inflammatory cytokines, including interleukin (IL)-4 [26].
and combined tumour necrosis factor (TNF)-α and interferon (IFN)-γ [27] in T84 cells. Additionally, EPA and DHA were shown to prevent permeability changes induced by mycotoxin, deoxynivalenol, and infection in a porcine epithelial cell model, IPEC-1, by preventing redistribution of tight junction proteins, claudin and ZO-1 [61]. Xiao et al. showed that incubation for 96 h with EPA, but not with DHA, was able to significantly attenuate increased permeability in heat stress-impaired Caco-2 monolayers [24].

Differing effects of EPA and DHA on gut permeability have been reported in vivo. Male Wistar rats subjected to heatstroke showed increased gut permeability, indicated by increased plasma D-lactate and endotoxin levels, which was attenuated by DHA, and even more effectively by EPA [33]. High-dose fish oil supplementation, containing both EPA and DHA and making up 15% total calories, prevented increased plasma endotoxin levels and decreased tight junction protein (ZO-1) expression in chronic ethanol-exposed male Wistar rats [47]. DHA also prevented increased plasma endotoxin levels in a necrotising enterocolitis model using Sprague–Dawley rats [41]. Dietary ω-3 PUFA supplementation in young male Sprague–Dawley rats had no effect on colitis-induced reductions in tight junction protein expression ( Claudin-1 and occludin) and barrier-associated protein expression (trefoil factor 3 and mucin 2) [49]. In other models of colitis, consumption of EPA-enriched fish oil protected intestinal absorption function [38] and transgenic mice with increased mucosal ω-3 PUFAs maintained ZO-1 tight junction protein expression [36]. Therefore, it seems the effects on ω-3 PUFAs on epithelial cell permeability may be dependent on the type of stimulus exerting changes to permeability, but could also be attributed to the dose and type of ω-3 PUFA used.
Table 4. Effects of ω-3 PUFAs on intestinal permeability in cell and rodent models.

| Reference          | Model Used | Condition                  | ω-3 PUFA(s) Used | Concentration or Dose Used | Duration | Changes to Permeability and Related Mechanisms |
|--------------------|------------|----------------------------|------------------|-----------------------------|----------|-----------------------------------------------|
| **Cell line models** |            |                            |                  |                             |          |                                               |
| Rosella et al. [23] | Caco-2 cells | Non-stimulated            | EPA              | 100 µg/mL                   | 24 h     | ↓ Permeability                                |
| Usami et al. [59]  | Caco-2 cells | Non-stimulated            | ALA, EPA         | 50–200 µM                   | 24 h     | ↑ Permeability, ↓ Electron-dense material at tight junctions and desmosomes (200 µM only) |
| Usami et al. [60]  | Caco-2 cells | Non-stimulated            | DHA              | 10–100 µM                   | 24 h     | ↑ Permeability (dose dependent)               |
| Willemsen et al. [26] | T84 cells | IL-4-induced inflammation | ALA, EPA, DHA    | 10 or 100 µM, 25–75 µM, 50 µM | 48 h, 96 h | ↓ Permeability, ↑ ZO-1 and occludin protein and mRNA expression |
| Li et al. [27]     | T84 cells | TNF-α- and IFN-γ-induced inflammation | EPA, DHA         | 25–75 µM, 50 µM            | 48 h, 96 h | ↓ Permeability, ↑ ZO-1 and occludin protein and mRNA expression |
| Xiao et al. [24]   | Caco-2 cells | Heat stress               | EPA, DHA         | 50 µM, Up to 25 µg/mL       | 24–72 h  | ↓ Permeability (24 and 48 h) |
| Xiao et al. [61]   | IPEC-1 cells | Deoxynivalenol-induced inflammation | EPA, DHA         | Up to 25 µg/mL              |          | ↓ Permeability (24 and 48 h) |

↑: Increased; ↓: Decreased; IL-4: Interleukin 4; IFN-γ: Interferon gamma; TNF-α: Tumor necrosis factor alpha; EPA: Eicosapentaenoic acid; ALA: Alpha-linolenic acid; DHA: Docosahexaenoic acid; TNF-α: Tumor necrosis factor alpha; IFN-γ: Interferon gamma; ZO-1: Zonula occludens 1; Occludin and flotillin: Tight junction protein redistribution; Tight junction altered morphology: Tight junction altered morphology; Electron-dense material at tight junctions and desmosomes (200 µM only): Electron-dense material at tight junctions and desmosomes (200 µM only); No effect on permeability: No effect on permeability; ↑ ZO-1 and occludin protein and mRNA expression: ↑ ZO-1 and occludin protein and mRNA expression; No effect on permeability: No effect on permeability.
Table 4. Cont.

| Reference       | Model Used            | Condition                  | \(\omega-3\) PUFA(s) Used       | Concentration or Dose Used  | Duration | Changes to Permeability and Related Mechanisms                        |
|-----------------|-----------------------|----------------------------|----------------------------------|-----------------------------|----------|------------------------------------------------------------------------|
| Rodent models   |                       |                            |                                  |                             |          |                                                                        |
| Empey et al. [38] | Male Sprague–Dawley rats | Acetic acid-induced colitis | EPA-enriched fish oil            | 10% by weight of total diet | 6 weeks  | Protected ileal and colonic absorption                                  |
| Caplan et al. [41] | Neonatal Sprague–Dawley rats | Necrotising enterocolitis | DHA                              | 23 mg/100 mL formula        | 96 h     | ↓ Plasma endotoxin level                                               |
|                  |                       |                            |                                  |                             |          |                                                                        |
| Hudert et al. [36] | Transgenic fat-1 mice | DSS colitis                | -                                | Mice have higher colonic EPA, DPA and DHA | -        | ↑ ZO-1 expression (maintained compared to colitis control)             |
|                  |                       |                            |                                  |                             |          |                                                                        |
| Xiao et al. [33] | Male Wistar rats      | Heatstroke                 | EPA                              | 1 g/kg body weight/day by gavage | 21 days  | ↓ Intestinal permeability                                              |
|                  |                       |                            |                                  |                             |          | ↓ Plasma endotoxin and D-lactate levels                                |
|                  |                       |                            |                                  |                             |          | ↑ Tight junction protein distortion                                    |
|                  |                       |                            |                                  |                             |          | ↑ Tight junction protein expression                                    |
|                  |                       |                            | DHA                              |                             |          |                                                                        |
| Charpentier et al. [49] | Young male Sprague–Dawley rats | TNBS colitis | \(\omega-3\) PUFAs (source not specified but presumed to be fish oil) | 6.1 g/kg of diet       | 28 days  | No effect on claudin-1 protein expression                               |
|                  |                       |                            |                                  |                             |          | No effect on occludin protein expression                               |
|                  |                       |                            |                                  |                             |          | No effect on TTF3 protein expression                                   |
|                  |                       |                            |                                  |                             |          | No effect on MUC2 protein expression                                   |
| Chien et al. [47] | Male Wistar rats      | Chronic ethanol exposure   | Fish oil                         | 7.1 or 16.2 g/kg diet       | 8 weeks  | ↓ Plasma endotoxin levels                                              |
|                  |                       |                            |                                  |                             |          | ↑ ZO-1 immunoreactive area in intestinal epithelial tissue (16.2 g/kg/day only) |

Abbreviations used: ALA, \(\alpha\)-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DSS, dextran sodium sulphate; EPA, eicosapentaenoic acid; ETE, eicosatrienoic acid; IFN, interferon; IL, interleukin; PUFA, polyunsaturated fatty acid; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumour necrosis factor; ZO, zonula occludens.
6. ω-3 PUFAs and Intestinal Epithelial Inflammation

Epithelial cells respond to a plethora of stimuli, both from luminal contents and the inflammatory milieu of the intestinal mucosa. The production of inflammatory mediators is governed by the cellular response to particular stimuli, and can be modulated by ω-3 PUFAs. The effects of ω-3 PUFAs on inflammatory mediator production by intestinal epithelial cells are summarised in Table 5.

Wang et al. demonstrated that, under non-inflammatory conditions, long-term (up to 90 days) fish oil consumption (40 g/kg body weight, containing 15.4% EPA and 15.1% DHA) in male Lewis rats significantly reduced cytokine mRNAs in the intestinal epithelium, including TNF-α, IFN-γ, IL-4, IL-10, and IL-15, as well as IL-15 protein expression, but had no effect on IL-7, and altered the phenotype of intraepithelial lymphocytes [62]. Acute exposure (12 h) to EPA or to DHA significantly upregulated transforming growth factor (TGF)-β1 mRNA expression in HT29 cells, and EPA, but not DHA, treatment induced a significant increase in TGF-β1 mRNA expression in mucus-secreting HT29-MTX cells [63]. Neither EPA nor DHA had a consistent effect on IL-7, and HSP 72 mRNA expression in HT29 or HT29-MTX cell cultures [63].

Inflammatory challenge alters epithelial cell inflammatory mediator production, as shown in Figure 3. This is considered to be damaging to epithelial barrier integrity, and it is thought that ω-3 PUFAs can regulate these processes. Pre-incubation with EPA and DHA, but not ALA, significantly prevented IL-1β-induced increases in IL-6 and IL-8 production in Caco-2 cells [64]. In a separate model using necrotising enterocolitis epithelial cells (H4 and NEC-IEC) and Caco-2 cells, IL-8 mRNA and protein expression were attenuated by DHA, after IL-1β treatment, in all cell lines [65]. IL-1β-induced increases in IL-6 mRNA and protein were attenuated by DHA and EPA but only in H4 cells [65]. In a model of IL-1β-induced inflammation in Caco-2 cells, both ALA-rich sage oil and ALA inhibited increased IL-8 expression [32]. Separate DHA or EPA supplementation inhibited increased IL-8 expression in a colonic epithelial cell line, HCT116, treated with the nucleotide-binding oligomerization domain-containing protein (NOD) 2 ligand, muramylidipeptide (MDP) [66]. DHA, but not EPA, supplementation also inhibited increased HCT116 IL-8 expression induced by lauric acid and the nucleotide-binding oligomerization domain-containing protein (NOD) 1 agonist, γ-D-glutamyl-mesodiaminopimelic acid (IE-DAP) [66]. DHA also reduced prostaglandin (PG) E2 and IL-8 production in Caco-2 cells stimulated with a digest of α-gliadin [67].

In an in vivo TNBS colitis model, ALA-rich camelina oil supplementation had no effect on IL-1β expression and secretion and the production of PGE2, but did significantly reduce TNF-α mRNA and protein, as well as leukotriene (LT) B4 production, in colonic tissue [44]. IL-10-deficient mice supplemented with DHA for 14 days had significantly reduced expression of TNF-α, IFN-γ, and IL-17 in the colonic mucosa [46]. Male Sprague–Dawley rats fed EPA and DHA for 3 weeks, before intestinal reperfusion and ischaemia, showed no alteration in cytokine production [31]. However, EPA-derived metabolites including thromboxane (TX) B3, 17,18-epoxyeicosatriaenoic acid (EET), and 8-iso PGF3α were significantly increased in intestinal tissue [31].

Hillier et al. demonstrated that humans given fish oil over a 12 week period had attenuated colonic levels of AA-derived metabolites, PGE2 and TXB2 [34]. However, ω-3 PUFA supplementation in male Sprague–Dawley rats showed a large (30-fold) increase in PGE2 and a smaller increase in LTB4 [38]. This is unexpected, as PGE2 synthesis is attributed to COX-2 processing of AA, and ω-3 PUFAs reduce AA availability and inhibit its metabolism by COX-2. EPA can also be processed by COX-2 to PGE3, which is known to be cross-reactive in PGE2 assays and may explain the large increase in “PGE2” seen. Alternatively, after ω-3 PUFA supplementation, free AA released from cell membranes as a result of ω-3 PUFA incorporation could be processed by COX-2 to form PGE2, contributing to the increase in PGE2 seen.
Table 5. Effects of ω-3 PUFAs on inflammatory mediators in cell, rodent and human models.

| Reference              | Model Used                  | Condition                      | ω-3 PUFA(s) Used | Dose Used | Duration | Effect on Inflammatory Mediator(s)               |
|------------------------|-----------------------------|--------------------------------|------------------|-----------|----------|------------------------------------------------|
|                       |                             | **Cell line models**           |                  |           |          |                                                |
| Zhao et al. [66]       | HCT116 cells                | Lauric acid/IE-DAP/MDP-induced inflammation | EPA              | 0–20 μM  | 20 h     | ↓ IL-8 protein (MDP only)                       |
|                       |                             |                                | DHA              |           |          |                                                |
| Marion-Letellier et al. [64] | Caco-2 cells              | IL-1β-induced inflammation    | EPA              | 0.1–10 μM | 18 h     | ↓ IL-6 protein                                  |
|                       |                             |                                | DHA              |           |          | ↓ IL-8 protein                                  |
|                       |                             |                                | DHA              |           |          | ↓ IL-6 protein                                  |
|                       |                             |                                | DHA              |           |          | ↓ IL-8 protein                                  |
| Vincentini et al. [67] | Caco-2 cells                | α-gliadin-induced inflammation | DHA              | 2 μM      | 24 h     | ↓ PGE₂                                          |
|                       |                             |                                | DHA              |           |          | ↓ IL-8 protein                                  |
| Bentley-Hewitt et al. [63] | HT29/HT29-MTX cell co-culture | Non-stimulated                | EPA              | 50 μM     | 12 h     | ↑ TGF-β1 mRNA                                   |
|                       |                             |                                | DHA              |           |          | No consistent effect on IL-8 or HSP 72 mRNA     |
|                       |                             |                                | DHA              |           |          | ↑ TGF-β1 mRNA                                   |
|                       |                             |                                | DHA              |           |          | No consistent effect on IL-8 or HSP 72 mRNA     |
| Reifen et al. [32]     | Caco-2 cells                | IL-1β-induced inflammation    | Sage oil (providing ALA) | 10 μM    | 48 h     | ↓ IL-8 protein                                  |
|                       |                             |                                | ALA              |           |          |                                                |
| Wijendran et al. [65]  | H4/NEC-IEC/Caco-2 cells     | IL-1β-induced inflammation    | EPA              | 100 μM    | 48 h     | ↓ IL-8 mRNA and protein (H4 only)                |
|                       |                             |                                | DHA              |           |          | ↓ IL-6 mRNA and protein (H4 only)                |
|                       |                             |                                | DHA              |           |          | ↓ IL-8 mRNA and protein (H4 only)                |
|                       |                             |                                | DHA              |           |          | ↓ IL-6 mRNA and protein (H4 and NEC-IEC)         |
|                       |                             |                                | DHA              |           |          | ↓ IL-6 protein (H4 and NEC-IEC)                  |
|                       |                             | **Rodent models**              |                  |           |          |                                                |
| Empey et al. [38]      | Rats                        | Non-stimulated                | EPA-enriched fish oil | 10% by weight of total diet | 6 weeks | ↑ PGE₂ in colonic dialysate                      |
|                       |                             |                                | DHA              |           |          | ↑ LTB₄ in colonic dialysate                      |
| Yuceyar et al. [40]    | Male Wistar albino rats     | TNBS colitis                  | Fish oil         | EPA: 14.4 mg/g diet | 6 weeks (diet) | ↓ Colonic LTB₄                                  |
|                       |                             |                                |                  | DHA: 11.6 mg/g diet |           | ↓ Colonic LTB₄                                  |
|                       |                             |                                |                  |           |          | ↓ Colonic LTB₄                                  |
|                       |                             |                                |                  |           |          | ↓ Colonic LTB₄                                  |
|                       |                             |                                |                  |           |          | ↓ Colonic LTB₄                                  |
| Reference               | Model Used              | Condition     | ω-3 PUFA(s) Used     | Dose Used          | Duration                        | Effect on Inflammatory Mediator(s)                                      |
|------------------------|-------------------------|---------------|----------------------|--------------------|---------------------------------|------------------------------------------------------------------------|
| Andoh et al. [42]      | Male Sprague–Dawley rats | TNBS colitis  | ω-3 PUFA-rich liquid diet (providing ALA) | 150 mg/100 kcal    | 12 days (followed by 2 days starvation) | ↓ Mucosal IL-6 secretion  
No effect on mucosal TNF-α secretion |
| Hudert et al. [36]     | Transgenic fat-1 mice   | DSS colitis   | -                    | Mice have higher colonic EPA, DPA and DHA than controls | -                               | ↑ Mucosal RvE1  
↑ Mucosal RvD3  
↑ Mucosal protectin D1  
↑ Mucosal PGE3  
↑ Mucosal LTB5  
No effect on mucosal LTB4  
No effect on mucosal PGE2  
No effect on mucosal 15-hydroxyeicosatetraenoic acid (lipoxin A4 precursor)  
↓ Colonic TNF-α mRNA  
↓ Colonic IL-1β mRNA  
↑ Colonic toll-interacting protein mRNA  
↑ Colonic trefoil factor 3 mRNA |
| Wang et al. [62]       | Male Lewis rats         | Non-stimulated | Fish oil             | Fish oil 4% by weight of total diet (EPA: 15.4% of total fatty acids; DHA: 15.1% of total fatty acids) | up to 90 days               | ↓ Mucosal LTB4  
No effect on IL-6 expression or secretion  
No effect on PGE2 |
| Hassan et al. [44]     | Male Sprague–Dawley rats | TNBS colitis  | ALA                  | 28.8% of total fat content of formula | 2 weeks                        | ↓ Mucosal LTB4  
No effect on IL-6 expression or secretion  
No effect on PGE2 |
Table 5. Cont.

| Reference                  | Model Used                  | Condition                                      | ω-3 PUFA(s) Used                                      | Dose Used                      | Duration | Effect on Inflammatory Mediator(s)                                                                 |
|----------------------------|-----------------------------|-----------------------------------------------|------------------------------------------------------|--------------------------------|----------|---------------------------------------------------------------------------------------------------|
| Bosco et al. [30]          | Rag2−/− immunodeficient mice| Adoptive transfer of naïve T-cell-induced colitis | Fish oil                                             | EPA: 3.37 g/100 g diet        | 8 weeks  | ↑ Colonic myeloperoxidase  
|                            |                             |                                               |                                                      | DHA: 2.10 g/100 g diet       |          | ↑ Colonic IL-1β protein  
|                            |                             |                                               |                                                      |                                |          | ↑ Colonic IL-12 protein  
|                            |                             |                                               |                                                      |                                |          | ↑ Colonic keratinocyte-derived chemokine protein  
|                            |                             |                                               |                                                      |                                |          | ↑ Colonic IL-10 protein  
|                            |                             |                                               |                                                      |                                |          | ↑ Colonic TNF-α protein  
|                            |                             |                                               |                                                      |                                |          | ↑ Mucosal PGE₃  
|                            |                             |                                               |                                                      |                                |          | ↑ Mucosal TXB₃  
|                            |                             |                                               |                                                      |                                |          | ↑ Mucosal LTB₅  
|                            |                             |                                               |                                                      |                                |          | ↑ Mucosal 5-HEPE  
|                            |                             |                                               |                                                      |                                |          | ↑ Mucosal 17,18-EET  
|                            |                             |                                               |                                                      |                                |          | ↓ Mucosal PGJ₂  
|                            |                             |                                               |                                                      |                                |          | ↓ Mucosal 5,6-EET  
|                            |                             |                                               |                                                      |                                |          | ↓ Mucosal 8,9-EET  
|                            |                             |                                               |                                                      |                                |          | ↓ Mucosal 14,15-EET  
|                            |                             |                                               |                                                      |                                |          | No effect on mucosal PGE₂  
|                            |                             |                                               |                                                      |                                |          | No effect on mucosal TXB₂  
|                            |                             |                                               |                                                      |                                |          | No effect on mucosal LTB₄  |
| Brahmabhett et al. [31]    | Male Sprague–Dawley rats   | Intestinal reperfusion and ischaemia          | EPA and DHA                                          | EPA: 3.00% of dietary fatty acids  
|                            |                             |                                               |                                                      | DHA: 1.98% of dietary fatty acids | 3 weeks  | ↑ TXB₃  
|                            |                             |                                               |                                                      |                                |          | ↑ 17,18-EET  
|                            |                             |                                               |                                                      |                                |          | ↑ 8-iso PGF₃,₆,₉α  |
| Zhao et al. [46]           | Mice                        | IL-10 deficient                               | DHA                                                 | 35.5 mg/kg body weight per day intragastrically | 2 weeks  | ↓ TNF-α protein  
|                            |                             |                                               |                                                      |                                |          | ↓ IFN-γ protein  
|                            |                             |                                               |                                                      |                                |          | ↓ IL-17 protein  |
| Charpentier et al. [49]    | Young male Sprague–Dawley rats | TNBS colitis (source not specified but presumed to be fish oil) | ω-3 PUFAs                                            | 6.1 g/kg of diet               | 28 days  | ↓ Colonic IL-6 protein  
|                            |                             |                                               |                                                      |                                |          | ↓ Colonic LTB₄  
|                            |                             |                                               |                                                      |                                |          | No effect on colonic TNF-α protein  |
| Yao et al. [48]            | Male Sprague–Dawley rats   | TNBS colitis (source not specified but presumed to be fish oil) | ω-3 PUFAs                                            | 20 mg/kg body weight per day intragastrically | 60 days  | ↓ Colonic IL-2 mRNA  
|                            |                             |                                               |                                                      |                                |          | ↓ Colonic IL-4 mRNA  |
### Table 5. Cont.

| Reference          | Model Used   | Condition          | ω-3 PUFA(s) Used | Dose Used                  | Duration | Effect on Inflammatory Mediator(s)                                                                 |
|--------------------|--------------|--------------------|------------------|----------------------------|----------|--------------------------------------------------------------------------------------------------|
| Zheng et al. [52]  | Male C57 mice| DSS colitis        | DPA              | 300 mg/kg body weight per day by gavage | 28 days  | ↓ Colonic IL-1β mRNA and protein ↓ Colonic IL-6 mRNA and protein ↓ Colonic TNF-α mRNA and protein ↑ Colonic IL-10 mRNA and protein ↓ Colonic PGE₂ ↓ Colonic LTB₄ |
| Hillier et al. [34] | Human        | Inflammatory bowel disease | Fish oil | Fish oil: 18 g/day (3.3 g EPA and 2.2 g DHA per day) | 12 weeks | ↓ Colonic mucosa PGE₂ ↓ Colonic mucosa TXB₂                                                                                                                                 |

Abbreviations used: ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DSS, dextran sodium sulphate; EEP, epoxyeicosatetraenoic acid; EET, epoxyeicosatrienoic acid; EPA, eicosapentaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HSP, heat shock protein; IE-DAP, γ-D-glutamyl-mesodiaminopimelic acid; IFN, interferon; IL, interleukin; LT, leukotriene; MDP, muramyl dipeptide; PG, prostaglandin; PUFA, polyunsaturated fatty acid; Rv, resolvin; TGF, transforming growth factor; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumour necrosis factor; TX, thromboxane.
Figure 3. IL-8 and monokine induced by gamma interferon (MIG) production by Caco-2 cells stimulated with a cocktail of cytokines (TNF-α (5 ng/mL), IFN-γ (50 ng/mL), and IL-1β) in a Transwell system; cytokines were added to the basolateral compartment, and apical and basolateral supernatants assessed for IL-8 and MIG by Luminex. Controls are unstimulated. (a): Apical IL-8 production. (b): Basolateral IL-8 production. (c): Apical MIG production. (d): Basolateral MIG production. Data are the mean ± SEM from three experiments and are not previously published. Significance was determined by one-way ANOVA with Dunnett’s multiple comparison tests; ** p < 0.01, *** p < 0.001, and **** p < 0.0001.

In TNBS colitis models, rats fed a diet rich in ω-3 PUFAs had decreased colonic concentrations of IL-2 and IL-4 [48], as well as IL-6, but there was no effect on TNF-α [42,49]. In a mouse model of immunodeficiency-induced colitis, 8 week fish oil supplementation had no effect on mucosal PGE₂, TXB₂ or LTB₄, but upregulated other colonic inflammatory mediators, including TNF-α, IL-1β, IL-12, myeloperoxidase (MPO), and keratinocyte-derived chemokine [30]. EPA- and DHA-derived metabolites including PGE₃, TXB₃, LTB₅, 5-hydroxyeicosapentaenoic acid (HEPE), and 17,18-EEP were increased after fish oil supplementation, whilst AA-derived metabolites PGJ₂, 5,6-epoxyeicosatrienoic acid (EET), 8,9-EET, and 14,15-EET were decreased [30]. In a separate colitis model, fish oil given through the diet or by enema also attenuated colonic levels of AA-derived metabolites, LTB₄ and LTC₄ [40].

DPA also altered inflammatory mediator production in a model of colitis in C57 mice. DPA supplementation for 4 weeks decreased colonic IL-1β, IL-6, and TNF-α mRNA and protein, as well as increasing colonic IL-10 [52]. Increases in AA-derived metabolites, PGE₂ and LTB₄ were also attenuated by DPA supplementation, suggesting that DPA, like EPA and DHA, competitively inhibits AA metabolism by COX and lipoxygenase (LOX) enzymes [52]. In a model of DSS colitis, mice with elevated epithelial cell levels of EPA, DPA and DHA as a result of a transgenic manipulation, also had increased mucosal levels of...
ω-3 PUFAs-derived metabolites, including resolvin D3, resolvin E1, protectin D1, PGE₃, and LTB₅ [36]. However, AA-derived metabolites, LTB₄, PGE₂, and 15-hydroxyeicosatetraenoic acid, were unaffected. The increase in TNF-α and IL-1β mRNA in response to DSS was attenuated in these mice, whilst toll-interacting protein and trefoil factor 3 mRNAs were upregulated in colonic mucosa [36].

Overall, supplementation with ω-3 PUFAs seems to upregulate the production of pro-resolving ω-3-derived mediators through COX and LOX enzyme processing and modulation of inflammatory pathways, as well as attenuating the production of pro-inflammatory chemokines, cytokines and eicosanoids. Varying effects seen between ω-3 PUFA treatments could be associated to the mechanisms of the specific inflammatory condition, the dose of ω-3 PUFAs used, and the time of exposure to the ω-3 PUFA supplementation.

7. Effect of ω-3 PUFAs on Inflammatory Signalling Pathways in Intestinal Epithelial Cells

The attenuation of inflammatory mediator production (as described above) is associated with the incorporation of ω-3 PUFAs into membranes, but ω-3 PUFAs also interact with surface membrane and intracellular receptors and intrinsic inflammatory pathway regulators; these effects are summarised Table 6.

DHA induced significant increases in PPAR-α and PPAR-γ activity, which coincided with significantly decreased triglyceride and apolipoprotein B release by Caco-2 cells [68]. EPA also induced significant upregulation of PPAR-α, but had no significant effect on PPAR-γ. EPA and DHA had no effect on PPAR-δ activity in vitro [68]. Additionally, postprandial triglyceride release in vivo was also inhibited by DHA treatment (but not by EPA) through a PPAR-α-dependent mechanism, as this effect was diminished in PPAR-α-deficient C57BL/6 mice [68]. The relevance of these findings is that PPARs, especially PPAR-γ, are anti-inflammatory and these studies show that they can be activated by EPA and DHA. In a separate model, PPAR-γ expression was upregulated by both EPA and DHA in IL-1β-treated Caco-2 cells [64]. ALA had no effect on PPAR-γ expression in either IL-1β-stimulated Caco-2 cells [64] or colonic tissue of TNBS-treated male Sprague–Dawley rats [44]. Additionally, EPA had no effect on PPAR-α mRNA expression in either Caco-2 or T84 epithelial cell lines [28]. Although variable effects have been seen on PPAR expression, assessing the activation of these receptors, through associated downstream mechanisms, such as NF-κB and iNOS, gives further insight into the action of ω-3 PUFAs.

DHA attenuated NF-κB activation and the degradation of the NF-κB inhibitory subunit, IκBα, induced by lauric acid, MDP, and IE-DAP treatment in HCT116 cells, whilst EPA had no effect [66]. DHA, but not EPA, attenuated NF-κB and IL-1R1 mRNA expression in IL-1β-treated H4 and Caco-2 cells [65]. ALA supplementation inhibited the activation of NF-κB and expression of the oxidative stress mediator, iNOS, in colonic tissue of TNBS-treated male Sprague–Dawley rats but had no effect on phosphorylation of downstream regulators, including JNK, P38, and IκB [44]. Increased ω-3 PUFA content of colonic tissue, through transgenic modification, attenuated increased NF-κB activation and iNOS mRNA expression [36]. IL-1β treatment induced iNOS expression in Caco-2 cells, which was attenuated by EPA and DHA supplementation, but not by ALA supplementation [64]. Conversely, ALA supplementation in a similar model, using IL-1β-stimulated Caco-2 cells, significantly reduced iNOS expression [32] and DHA supplementation had no effect on iNOS expression in colonic tissue from a neonatal Sprague–Dawley rat necrotising enterocolitis model [41]. Disparate findings from these studies could be linked to ω-3 PUFA dose or to the precise inflammatory mechanisms involved in the different models, as necrotising enterocolitis is driven by a multitude of inflammatory mediators, including platelet-activating factor (PAP), TNF-α, and a variety of interleukins [69].

COX-2 activity and expression, which is involved in the production of PGs from AA, can be regulated by ω-3 PUFAs. In male Wistar rats treated with TNBS or DSS to induce colitis, both fish oil and sage oil (rich in ALA) decreased COX-2 mRNA expression in colonic tissue [32]. ALA supplementation in TNBS-stimulated Sprague–Dawley rats also decreased COX-2 expression in colonic tissue [44]. Additionally in vitro, ALA and
sage oil treatment inhibited COX-2 expression in IL-1β-stimulated Caco-2 cells [32] and DHA supplementation of Caco-2 cells stimulated with α-gliadin also reduced COX-2 expression [67]. ω-3 PUFA supplementation suppressed colonic COX-2 expression, as well as increasing IL-1A, toll-like receptor (TLR) 2, and mitogen-activated protein kinase kinase 3 mRNA expression in a Sprague–Dawley rat model of TNBS-induced colitis [49]. DHA has also been shown to inhibit toll-like receptor 4 and PAF receptor mRNA expression in PAF-treated IEC-6 epithelial cultures [43]. PAF receptor and phospholipase A₂ expression were also suppressed by DHA in a neonatal Sprague–Dawley rat model of necrotising enterocolitis [41]. DHA treatment in HT-29 epithelial cultures altered cell maturation, with fewer cells in the stationary phase and increased numbers of cells in the G₀/G₁ phase of the cell cycle. Additionally, DHA potentiated TNF-α and anti-Fas antibody induced epithelial cell apoptosis [70]. Dietary fish oil supplementation in male Wistar rats reduced MPO activity in a model of TNBS colitis, whilst the same dose of fish oil given by enema had no effect on MPO activity [40]. It seems that the route or the mode of administration may affect the anti-inflammatory efficacy of fish oil in this model of colitis.

Microarray analysis has also shown that EPA and DHA can regulate a multitude of pathways across small intestinal tissue. Six hours after being given an oral dose of either EPA or DHA, small intestinal tissue resected from wild-type mice showed regulated responses to pathways involved in long-chain fatty acid uptake, peroxisomal β-oxidation, ω-oxidation, metabolism of energy-yielding substrates, and oxidative stress, as well as suppression of the cholesterol uptake transporter, Npc1l1, the apical mannose and glucose uptake transporter, Sglt4, and the serotonin transporter, Slc6a4. EPA treatment (but not DHA) also increased cholesterol efflux protein, Abca1, and dopamine transporter, Dat1, expression [71].
| Reference               | Model Used   | Condition                                      | ω-3 PUFA(s) Used | Concentration or Dose Used | Duration | Effect on Inflammatory Mechanisms(s)                                                                 |
|-------------------------|--------------|-----------------------------------------------|------------------|---------------------------|----------|-----------------------------------------------------------------------------------------------------|
| Hofmanová et al. [70]   | HT-29 cells  | TNF-α or anti-Fas monoclonal antibody/cycloheximide-induced inflammation | DHA              | 20 µM                     | 48 h     | ↑ G0/G1 phase cells <br>↑ Apoptosis (TNF-α and anti-Fas monoclonal antibody treatments)                  |
| Renaville et al. [28]   | T84/Caco-2 cells | Non-stimulated                              | EPA              | 300 M                     | 3 h or 3 h and 7 days | No effect on PPAR-α mRNA (both time periods) <br>↓ Stearoyl CoA desaturase and SREBP-1c mRNA (3 h and 7 days only) |
| Lu et al. [43]          | IEC-6 cells  | Platelet-activating factor treatment         | DHA              | 67 µM                     | 30 min   | ↓ TLR4 mRNA <br>↓ Platelet-activating factor receptor mRNA                                             |
| Zhao et al. [66]        | HCT116 cells | Lauric acid/IE-DAP/MDP-induced inflammation | DHA              | 0–20 µM                   | 20 h     | ↓ NF-κB activation <br>↓ IκB degradation                                                              |
| Marion-Letellier et al. [64] | Caco-2 cells | IL-1β-induced inflammation                   | ALA              | 0.1–10 µM                 | 18 h     | No effect on PPAR-γ protein <br>No effect on iNOS protein <br>No effect on IκB protein                  |
| Vincentini et al. [67]  | Caco-2 cells | α-gliadin-induced inflammation              | DHA              | 2 µM                      | 24 h     | ↓ Cytosolic phospholipase 2 activity <br>↓ COX-2 protein                                               |
| Reference          | Model Used       | Condition                        | \(\omega-3\) PUFA(s) Used | Concentration or Dose Used | Duration | Effect on Inflammatory Mechanisms(s) |
|--------------------|------------------|----------------------------------|-----------------------------|-----------------------------|----------|-----------------------------------|
| Kimura et al. [68] | Caco-2 cells     | Non-stimulated                   | DHA                         | 25 \(\mu\)M                | 24 h     | ↑ PPAR-\(\alpha\) activity       |
|                    |                  |                                  |                             |                             |          | ↑ PPAR-\(\gamma\) activity       |
|                    |                  |                                  |                             |                             |          | No effect on PPAR-\(\delta\) activity |
|                    |                  |                                  |                             |                             |          | ↓ Triglyceride and apolipoprotein B secretion |
|                    |                  |                                  | EPA                         |                             |          |                                  |
| Reifen et al. [32] | Caco-2 cells     | IL-1\(\beta\)-induced inflammation | Sage oil                    | 10 \(\mu\)M               | 48 h     | ↓ COX-2 protein                   |
|                    |                  |                                  | ALA                         |                             |          |                                  |
| Wijendran et al. [65] | H4/NEC-IEC/Caco-2 cells | IL-1\(\beta\)-induced inflammation | DHA                         | 100 \(\mu\)M              | 48 h     | ↓ NF-\(\kappa\)B mRNA             |
|                    |                  |                                  | EPA                         |                             |          | ↓ IL-1R1 mRNA                     |
| Yuceyar et al. [40] | Male Wistar albino rats | TNBS colitis                    | Fish oil                    | EPA: 14.4 mg/g diet         | 6 weeks (diet) | ↓ Myeloperoxidase activity |
|                    |                  |                                  |                             | DHA: 11.6 mg/g diet        |          |                                  |
|                    |                  |                                  |                             |                             | 14 days (daily enema) | No effect on myeloperoxidase activity |
| Caplan et al. [41] | Neonatal Sprague–Dawley rats | Necrotising enterocolitis      | DHA                         | 23 mg/100 mL formula       | 96 h     | No effect on iNOS protein       |
|                    |                  |                                  |                             |                             |          | ↓ Phospholipase \(A_2\) protein |
|                    |                  |                                  |                             |                             |          | ↓ Platelet-activating factor receptor protein |
| Hudert et al. [36] | Transgenic fat-1 mice | DSS colitis                    | -                           | Mice have higher colonic EPA, DPA and DHA than controls | - | ↓ Colonic NF-\(\kappa\)B activity |
|                    |                  |                                  |                             |                             |          | ↓ Colonic iNOS mRNA               |
### Table 6. Cont.

| Reference                          | Model Used                  | Condition          | ω-3 PUFA(s) Used | Concentration or Dose Used                   | Duration | Effect on Inflammatory Mechanisms(s)                                                                                                                                                                                                 |
|------------------------------------|-----------------------------|--------------------|------------------|-----------------------------------------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| de Vogel-van den Bosch et al. [71] | 129S1/SvImJ wild-type mice  | Non-stimulated     | DHA              | EPA or DHA: 12.5 g/kg body weight by gavage  | 6 h      | No effect on regulated long-chain fatty acid uptake, mitochondrial and peroxisomal β-oxidation, ω-oxidation, and metabolism of energy-yielding substrates No effect on regulated oxidative stress mRNAs ↓ Cholesterol uptake transporter (Npc1l1), apical mannose and glucose uptake transporter (Sglt4), and serotonin transporter (Slc6a4) |
| Hassan et al. [44]                 | Male Sprague–Dawley rats    | TNBS colitis       | ALA              | 28.8% of total fat content of formula        | 2 weeks  | ↓ Colonic iNOS protein ↓ Colonic COX-2 protein ↓ Colonic NF-κB activation No effect on phosphorylation of JNK, P38 and IκB                                                                                                                                                       |
Table 6. Cont.

| Reference          | Model Used  | Condition                   | ω-3 PUFA(s) Used | Concentration or Dose Used | Duration | Effect on Inflammatory Mechanisms(s) |
|--------------------|-------------|-----------------------------|------------------|-----------------------------|----------|--------------------------------------|
| Kimura et al. [68] | Male C57BL/6 mice | PPAR-α deficiency         | DHA-rich oil     | 60% energy fat diet with 1.9% or 3.7% of total fatty acids as DHA (plus some EPA) | 1 week   | ↓ Triglyceride secretion (inhibited by PPAR-α deficiency) with 3.7% DHA |
|                    |             |                             | EPA-rich oil     | 3.4% EPA and 1.5% DHA       |          |                                      |
| Reifen et al. [32] | Male Wistar rats  | TNBS- or DSS-induced colitis | Fish oil          | Fish oil: 5% by weight of total diet (EPA: 11.7% of total fatty acids DHA: 15.7% of total fatty acids) | 3 weeks  | ↓ COX-2 mRNA                        |
|                    |             |                             | Sage oil          | Sage oil: 5% by weight of total diet (ALA: 43.9% of total fatty acids) |          |                                      |
| Charpentier et al. [49] | Young male Sprague–Dawley rats | TNBS colitis | ω-3 PUFAs (source not specified but presumed to be fish oil) | 6.1 g/kg of diet | 28 days | ↑ Colonic IL-1A mRNA  
↑ Colonic TLR-2 mRNA  
↑ Colonic mitogen-activated protein kinase kinase 3 mRNA  
↓ Colonic iNOS protein  
↓ Colonic COX-2 protein |
| Yao et al. [48]    | Male Sprague–Dawley rats | TNBS colitis  | ω-3 PUFAs (source not specified but presumed to be fish oil) | 20 mg/kg body weight per day intra-gastrically | 60 days  | ↓ Colonic nuclear factor of activated T cells mRNA  
↑ Colonic PPAR-γ mRNA |
| Zheng et al. [52]  | Male C57 mice  | DSS colitis                  | DPA              | 300 mg/kg body weight per day by gavage | 28 days  | ↓ Colonic myeloperoxidase activity  
↓ Colonic COX protein  
↓ Colonic 5-LOX protein |

Abbreviations used: ALA, α-linolenic acid; COX, cyclooxygenase; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; DSS, dextran sodium sulphate; EPA, eicosapentaenoic acid; IE-DAP, γ-D-glutamylmesodiaminopimelic acid; IκB, inhibitory subunit of NF-κB; IL, interleukin; LOX, lipoxygenase; MDP, muramyl dipeptide; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NOS, nitric oxide synthase; PPAR, peroxisome proliferator activated receptor; PUFA, polyunsaturated fatty acid; SREBP, sterol receptor element-binding protein; TLR, toll-like receptor; TNBS, 2,4,6-trinitrobenzenesulfonic acid; TNF, tumour necrosis factor.
8. Gut Microbiota, Gut Inflammation, and ω-3 PUFAs

In addition to direct effects of ω-3 PUFAs on intestinal epithelial inflammation, it is important to consider the contribution of the microbiota to the regulation and maintenance of the gut epithelium–immune system axis and whether ω-3 PUFAs might mediate some of their actions via effects on the microbiota. Homeostatic mechanisms of the gut microbiota include anti-microbial protection, immunomodulation (through secretion of mediators and interaction with epithelial cells), maintenance of intestinal barrier integrity, and nutrient metabolism [72]. Microbial dysbiosis can contribute to the dysfunction of the intestinal barrier and the induction of intestinal inflammation [73]. Supplementation with ω-3 PUFAs has been shown to alter the composition of the gut microbiota across the life course in mouse models [74,75]; however, the evidence for ω-3 PUFA-induced modulation of the gut microbiota in humans is still relatively scarce. Djuric et al. have recently described that ω-3 PUFA consumption induced small changes to gut microbial populations in humans, which were associated with increased colonic EPA to arachidonic acid ratios and a reduction in colonic PGE2 expression [76]. Associations between increased favourable gut microbial populations and improved disease outcomes with ω-3 PUFA treatment have also been reported in obesity [77], rheumatoid arthritis [78] and cancer [79]. The microbial populations that appear to be promoted by increased ω-3 PUFA intake, including Bacteroidetes, Firmicutes, Lachnospiraceae, Bifidobacteria, and Enterobacteria, exhibit anti-inflammatory properties through increased production of SCFAs, particularly butyrate, and reduced endotoxaemia [80]. There is evidence that ω-3 PUFAs can be metabolised by particular bacterial species, resulting in the production of potential active metabolites, which could induce anti-inflammatory actions in the intestinal mucosa [81,82]. Further research into EPA, DPA and DHA metabolism by the gut microbiota and the subsequent effects on the gut epithelium could identify new anti-inflammatory mechanisms for ω-3 PUFAs.

9. ω-3 PUFAs and Human IBD

The pre-clinical research involving cell lines and rodent models described in earlier sections demonstrates the ability of ω-3 PUFAs to exert anti-inflammatory actions at the level of the intestinal epithelium. This would suggest a role for ω-3 PUFAs in preventing, and perhaps in treating, human inflammatory bowel diseases (IBD). Mozaffari et al. recently conducted a systematic review and meta-analysis of studies evaluating intake of fish or of different ω-3 PUFAs and risk of incident IBD [83]; studies were a mix of prospective cohort studies and case–control studies. An inverse association between fish consumption and the incidence of Crohn’s disease (effect size: 0.54) was observed, but there was no relationship between total dietary ω-3 PUFA intake and risk of IBD (effect size: 1.17) [83]. There was a significant inverse association between dietary EPA and DHA intake and the risk of IBD (effect size: 0.78) and ulcerative colitis (effect size: 0.75), but not of Crohn’s disease (effect size: 0.85). There was no association between ALA intake and IBD (effect size: 1.17) [83]. Thus, EPA and DHA, but not ALA, may protect against development of ulcerative colitis. With regard to the treatment of IBD, there have been a number of trials of ω-3 PUFAs (mainly preparations of EPA plus DHA) over the years; trials conducted prior to 2009 are reviewed in [84] while trials published since 2010 are reviewed in [85]. The focus of the majority of such human trials has not been on the function of the intestinal barrier and epithelial cells specifically, but rather on macroscopic inflammatory scores, relapse and remission rates, and systemic markers of inflammation such as plasma concentrations of cytokines. The findings from these trials are inconsistent. Several systematic reviews and meta-analyses of randomised controlled trials of ω-3 PUFAs in patients with IBD have been published [86–88]. Ajabnoor et al. recently published a large meta-analysis of 83 randomised controlled trials reporting on inflammatory outcomes and including over 41,000 participants [89]. Of these trials, 13 recruited patients with IBD. The meta-analysis identified that increasing intake of EPA and DHA may reduce risk of IBD relapse (relative risk 0.85) and of IBD worsening (relative risk 0.85); EPA and DHA also reduced
Foods, 10, 199

10. Summary, Concluding Remarks and Limitations of the Literature

Epithelial cells appear to easily incorporate ω-3 PUFAs both in vitro and in vivo. They also metabolise ALA to EPA and DHA. Overall, the literature supports the regulatory properties of marine-derived ω-3 PUFAs, EPA, DPA and DHA, and the plant-derived ω-3 PUFA, ALA, in intestinal epithelial cells and tissue. This regulatory role of ω-3 PUFAs in epithelial cells involves a number of mechanisms (Figure 4), and these fatty acids appear to reduce responses of epithelial cells to many inflammatory stimuli both in vitro and in vivo and lead to improvements in inflammation-related outcomes in many animal models as well as in patients. EPA and DHA are incorporated fairly rapidly into cultured epithelial cells (over hours to days). Rodent models showed increased intestinal tissue ω-3 PUFA composition after fish oil consumption, over longer supplementation periods (7–21 days), but shorter periods have not been frequently investigated. Two human studies indicated that fish oil supplementation over 12 weeks and 1 year altered ω-3 PUFA content in colonic and rectal tissue, respectively [34,35]. Therefore, it seems that complexity of the model (human > rodent > cell) is correlated with the time period required to alter ω-3 PUFA content of intestinal tissue.

Histological improvements after ω-3 PUFA supplementation in rodents have been reported in a range of inflammatory conditions, including various forms of colitis, haemorrhagic shock, IL-10 deficiency, β-lactoglobulin-induced inflammation, and peritoneal colitis. However, in some studies of colitis and a model of chronic ethanol exposure, no benefit of ω-3 PUFAs was seen. The specific protective effect or lack of effect seen could
be attributed to the specific ω-3 PUFA used, the dose of ω-3 PUFAs, the inflammatory condition, or a combination of these factors.

Investigations using cell and rodent models have explored the effects of ω-3 PUFAs on specific inflammatory outcomes including permeability, inflammatory mediator production, and regulation of inflammatory proteins. ω-3 PUFA supplementation was shown to influence permeability by preventing tight junction protein redistribution or changes to tight junction protein expression in cell models of cytokine-induced inflammation, heat stress, and deoxynivalenol-induced inflammation, and in rodent models of DSS-induced and acetic acid-induced colitis, necrotising enterocolitis, heatstroke, and chronic ethanol exposure. However, in one rodent model of TNBS-induced colitis, ω-3 PUFA treatment had no effect on permeability-associated protein expression [49].

Inflammatory cytokines, such as IL-6 and IL-8, were attenuated by ω-3 PUFA supplementation in several different inflammatory conditions, including IL-1β-induced inflammation, lauric acid-induced inflammation, α-gliadin-induced inflammation, and TNBS-induced colitis. Additionally, PUFA-derived metabolites were altered after ω-3 PUFA supplementation, although the findings varied across different models. Inflammatory regulators responsible for alterations in mediator production, such as NF-κB, iNOS, COX-2, and PPARs, were altered by ω-3 PUFA supplementation in various cell and rodent models.

Thus, the current body of literature highlights a large range of interacting mechanisms of action of ω-3 PUFAs by which they reduce epithelial inflammation; these mechanisms are identified in both cell models and in rodents. Nevertheless, it remains unclear which ω-3 PUFA is most effective, although comparator studies suggest this might be DHA, and the actual primary mechanism(s) within each different inflammatory condition is not clear. Further to this, ω-3 PUFAs modify the gut microbiota in ways that might reduce epithelial inflammation. In addition, gut microbes can metabolise ω-3 PUFAs to bioactive anti-inflammatory mediators. Through their multiple anti-inflammatory actions, ω-3 PUFAs, especially EPA and DHA, would be expected to reduce risk of human IBD and perhaps even improve outcomes in patients with existing IBD. In both regards, the existing literature is inconsistent. However, recent systematic reviews and meta-analyses indicate that EPA and DHA, but not ALA, may protect against development of ulcerative colitis [83] and may reduce the risk of IBD relapse and worsening [89].

One limitation of the current literature is the large variety of concentrations/doses of ω-3 PUFAs used across the different models. In some cases, the concentrations used in vitro models and the doses used in vivo rodent models are extremely high and therefore hard to translate to the human equivalent diet. A second limitation is a lack of human studies investigating the intestinal epithelium in the context of altered ω-3 PUFA exposure. Most studies have focused on EPA and DHA, with a number of in vitro and some animal studies of ALA. DPA is emerging as a bioactive ω-3 PUFA. Epithelial cells produce DPA [25,28] from EPA and there have been a small number of studies of DPA in intestinal epithelial models [36,52]; however, DPA requires greater investigation in this context. Other underexplored ω-3 PUFAs such as stearidonic acid (18:4 ω-3) also deserve investigation using these models.

Author Contributions: Conceptualisation, L.A.D. and P.C.C.; writing—original draft preparation, L.A.D.; writing—review and editing, C.E.C. and P.C.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: Not applicable.

Conflicts of Interest: L.A.D. and C.E.C. declare no conflict of interest. P.C.C. acts as a consultant to BASF AS, Smartfish, DSM, Cargill, Danone/Nutricia and Fresenius-Kabi.

References
1. McCole, D.F.; Barrett, K.E. Varied role of the gut epithelium in mucosal homeostasis. Curr. Opin. Gastroenterol. 2007, 23, 647–654. [CrossRef] [PubMed]
2. Michielan, A.; D’Inca, R. Intestinal permeability in inflammatory bowel disease: Pathogenesis, clinical evaluation, and therapy of leaky gut. *Mediat. Inflamm.* 2015, 2015, 628157. [CrossRef] [PubMed]

3. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* 2016, 7, 189–200. [CrossRef] [PubMed]

4. Shi, N.; Li, N.; Duan, X.; Niu, H. Interaction between the gut microbiome and mucusal immune system. *Milit. Med. Res.* 2017, 4, 14. [CrossRef] [PubMed]

5. Guillot, X.; Semerano, L.; S aid enberg-Kermanac’h, N.; Falgarone, G.; Boissier, M.-C. Vitamin D and inflammation. *Joint Bone Spine* 2010, 77, 552–557. [CrossRef] [PubMed]

6. Souyou, S.A.; Saussy, K.P.; Lupo, M.P. Nutraceuticals: A review. *Dermatol. Ther.* 2018, 8, 5–16. [CrossRef] [PubMed]

7. Zhang, H.; Tsao, R. Dietary polyphenols, oxidative stress and antioxidant and anti-inflammatory effects. *Curr. Opin. Food Sci.* 2016, 8, 33–42. [CrossRef]

8. Tan, J.; McKenzie, C.; Potamitis, M.; Thorburn, A.N.; Mackay, C.R.; Macia, L. The Role of short-chain fatty acids in fish: The anti-inflammatory potential of long-chain omega-3 fatty acids. *Nutr. Rev.* 2010, 68, 280–289. [CrossRef] [PubMed]

9. Wall, R.; Ross, R.P.; Fitzgerald, G.F.; Stanton, C. Fatty acids from fish: The anti-inflammatory potential of long-chain omega-3 fatty acids. *Am. J. Clin. Nutr.* 2010, 885–897. [CrossRef] [PubMed]

10. Calder, P.C. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* 2015, 1851, 469–484. [CrossRef]

11. Calder, P.C. Omega-3 fatty acids and inflammatory processes: From molecules to man. *Biochem. Soc. Trans.* 2017, 45, 1105–1115. [CrossRef] [PubMed]

12. de Bus, I.; Witkamp, R.; Zuilhof, H.; Albada, B.; Bal vers, M. The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation. *Prostagland. Other Lipid Mediat.* 2019, 144, 106531. [CrossRef] [PubMed]

13. Innes, J.K.; Calder, P.C. Marine omega-3 (n-3) fatty acids for cardiovascular health: An update for 2020. *Int. J. Mol. Sci.* 2020, 21, 1362. [CrossRef] [PubMed]

14. Miles, E.A.; Calder, P.C. Influence of marine n-3 polyunsaturated fatty acids on immune function and a systematic review of their effects on clinical outcomes in rheumatoid arthritis. *Brit. J. Nutr.* 2012, 107, S171–S184. [CrossRef]

15. Calder, P.C. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. *Mol. Nutr. Food Res.* 2008, 52, 885–897. [CrossRef]

16. Shahidi, F.; Ambigaipalan, P. Omega-3 polyunsaturated fatty acids and their health benefits. *Ann. Rev. Food Sci. Technol.* 2018, 9, 345–381. [CrossRef]

17. Calder, P.C. Is increasing microbiota diversity a novel anti-inflammatory action of marine n-3 fatty acids? *J. Nutr.* 2019, 149, 1102–1104. [CrossRef]

18. Arterburn, L.M.; Hall, E.B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. *Am. J. Clin. Nutr.* 2006, 83, 1467S. [CrossRef]

19. Derikx, J.P.M.; Luyer, M.D.P.; Heineman, E.; Buurman, W.A. Non-invasive markers of gut wall integrity in health and disease. *World J. Gastroenterol.* 2010, 16, 5272–5279. [CrossRef]

20. Cencić, A.; Langerhole, T. Functional cell models of the gut and their applications in food microbiology—A review. *Int. J. Food Microbiol.* 2010, 141, S4–S14. [CrossRef]

21. Simon-Assmann, P.; Turck, N.; Sidhoum-Jenny, M.; Gradwohl, G.; Kedinger, M. In Vitro models of intestinal epithelial cell differentiation. *Cell Biol. Toxicol.* 2007, 23, 241–256. [CrossRef] [PubMed]

22. Sakolish, C.M.; Esch, M.B.; Hickman, J.J.; Shuler, M.L.; Mahler, G.J. Modeling barrier tissues In Vitro: Methods, achievements, and challenges. *EBioMed* 2016, 5, 30–39. [CrossRef] [PubMed]

23. Rosella, O.; Sinclair, A.; Gibson, P.R. Polyunsaturated fatty acids reduce non-receptor-mediated transcellular permeation of protein across a model of intestinal epithelium in vitro. *J. Gastroenterol. Hepatol.* 2000, 15, 626–631. [CrossRef] [PubMed]

24. Xiao, G.; Tang, L.; Yuan, F.; Zhu, W.; Zhang, S.; Liu, Z.; Su, L. Eicosapentaenoic acid enhances heat stress-impaired intestinal epithelial barrier function in Caco-2 cells. *Plos ONE* 2013, 8, e73571. [CrossRef] [PubMed]

25. Beguin, P.; Schneider, A.-C.; Mignolet, E.; Schneider, Y.-J.; Larondelle, Y. Polyunsaturated fatty acid metabolism in enterocyte models: T84 cell line vs. Caco-2 cell line. *In Vitro Cell Dev. Biol. Anim.* 2014, 50, 111–120. [CrossRef]

26. Willemsen, L.E.; Koetsier, M.A.; Bal vers, M.; Beermann, C.; Stahl, B.; van Tol, E.A. Polyunsaturated fatty acids support epithelial barrier integrity and reduce IL-4 mediated permeability In Vitro. *Eur J. Nutr.* 2008, 47, 183–191. [CrossRef] [PubMed]

27. Li, Q.; Zhang, Q.; Wang, M.; Zhao, S.; Xu, G.; Li, J. n-3 polyunsaturated fatty acids prevent disruption of epithelial barrier function induced by pro-inflammatory cytokines. *Mol. Immunol.* 2008, 45, 1356–1365. [CrossRef]

28. Renaville, B.; Mullenn, A.; Moloney, F.; Larondelle, Y.; Schneider, Y.J.; Roche, H.M. Eicosapentaenoic acid and 3,10 dithia stearic acid inhibit the desaturation of trans-vaccenic acid into cis-9, trans-11-conjugated linoleic acid through different pathways in Caco-2 and T84 cells. *Brit. J. Nutr.* 2006, 95, 688–695. [CrossRef]

29. Nieto, N.; Torres, M.J.; Rios, A.; Gil, A. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. *J. Nutr.* 2002, 132, 11–19. [CrossRef]

30. Bosco, N.; Brahmhblatt, V.; Oliveira, M.; Martin, F.-P.; Lichti, P.; Raymond, F.; Benyacoub, J. Effects of increase in fish oil intake on intestinal eicosanoids and inflammation in a mouse model of colitis. *Lipids Health Dis.* 2013, 12, 81. [CrossRef]
31. Brahmbhatt, V.; Oliveira, M.; Briand, M.; Perrissou, G.; Schmid, V.B.; Destaillats, F.; Bosco, N. Protective effects of dietary EPA and DHA on ischemia–reperfusion-induced intestinal stress. J. Nutr. Biochem. 2013, 24, 104–111. [CrossRef] [PubMed]

32. Reifen, R.; Karlinsky, A.; Stark, A.H.; Berkovich, Z.; Nyska, A. α-Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease. J. Nutr. Biochem. 2015, 26, 1632–1640. [CrossRef] [PubMed]

33. Xiao, G.; Yuan, F.; Geng, Y.; Qu, X.; Liu, Z.; Lu, J.; Su, L. Eicosapentaenoic acid enhances heatstroke-impaired intestinal epithelial barrier function in rats. Shock 2015, 44, 348–356. [CrossRef] [PubMed]

34. Hillier, K.; Jewell, R.; Dorrell, L.; Smith, C. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991, 32, 1151–1155. [CrossRef]

35. Hawthorne, A.; Daneshmend, T.; Hawkey, C.; Belluzzi, A.; Everitt, S.; Holmes, G.; Willars, J.E. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12 month randomised controlled trial. Gut 1992, 33, 922–928. [CrossRef]

36. Hudert, C.A.; Weylandt, K.H.; Lu, Y.; Wang, J.; Hong, S.; Dignass, A.; Kang, J.X. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 2006, 103, 11276–11281. [CrossRef]

37. Vilaseca, J.; Salas, A.; Guarrner, F.; Rodriguez, R.; Martinez, M.; Malagelada, J. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990, 31, 539–544. [CrossRef]

38. Empey, L.R.; Jewell, L.D.; Garg, M.L.; Thomson, A.B.; Clandinin, M.T.; Fedorak, R.N. Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats. Can. J. Physiol. Pharmacol. 1991, 69, 480–487. [CrossRef]

39. Shoda, R.; Matsueda, K.; Yamato, S.; Umeda, N. Therapeutic efficacy of N-3 polyunsaturated fatty acid in experimental Crohn’s disease. J. Gastroenterol. 1995, 30, 98–101. [CrossRef]

40. Yuceyar, H.; Ozutemiz, O.; Huseyinov, A.; Saruc, M.; Alkanat, M.; Bor, S.; Batur, Y. Is administration of n-3 fatty acids by mucosal enema protective against trinitrobenzeno-induced colitis in rats? Prostagland Leukot. Essent. Fat. Acids 1999, 61, 339–346. [CrossRef]

41. Caplan, M.S.; Russell, T.; Xiao, Y.; Amer, M.; Kaup, S.; Jilling, T. Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. Ped. Res. 2001, 49, 647–652. [CrossRef] [PubMed]

42. Andoh, A.; Tsujikawa, T.; Ishizuka, I.; Araki, Y.; Sasaki, M.; Koyama, Y.; Fujiyama, Y. N-3 fatty acid-rich diet prevents early inflammatory lesions in a rat model of granulomatous colitis. [CrossRef]

43. Lu, J.; Jilling, T.; Li, D.; Caplan, M.S. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Ped. Res. 2007, 61, 427–432. [CrossRef] [PubMed]

44. Hassan, A.; Ibrahim, A.; Mboodji, K.; Coeffier, M.; Ziegler, F.; Bounoure, F.; Marion-Setellier, R. An α-linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF-κB in rats with TNBS-induced colitis. J. Nutr. 2010, 140, 1714–1721. [CrossRef]

45. Li, Y.; Wang, X.; Li, N.; Li, J. The study of n-3 PUFAs protecting the intestinal barrier in rat HS/R model. Lipids Health Dis. 2014, 13, 146. [CrossRef]

46. Zhao, J.; Shi, P.; Sun, Y.; Sun, J.; Dong, J.N.; Wang, H.G.; Zhu, W.M. DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function. Brit. J. Nutr. 2015, 114, 181–188. [CrossRef]

47. Chien, Y.-W.; Peng, H.-C.; Chen, Y.-L.; Pai, M.-H.; Wang, H.-Y.; Chuang, H.-L.; Yang, S.C. Different dietary proportions of fish oil regulate inflammatory factors but do not change intestinal tight junction-ZO-1 expression in ethanol-fed rats. Mediat. Inflamm. 2017, 2017, 5801768. [CrossRef]

48. Yao, J.; Lu, Y.; Zhi, M.; Hu, P.; Wu, W.; Gao, X. Dietary n-3 polyunsaturated fatty acids ameliorate Crohn’s disease in rats by modulating the expression of PPAR-γ/NFAT. Mol. Med. Rep. 2017, 16, 8315–8322. [CrossRef]

49. Charpentier, C.; Chan, R.; Salameh, E.; Mboodji, K.; Ueno, A.; Coeffier, M.; Marion-Setellier, R. Dietary n-3 PUFA may attenuate experimental colitis. Mediat. Inflamm. 2018, 2018, 8430614. [CrossRef]

50. Haddi, A.; Guendouz, M.; Tabet, S.A.; Mehedi, N.; Kheroua, O.; Saidi, D. Polyunsaturated fatty acids affect intestinal anaphylactic response in BALB/c mice sensitized with β-lactoglobulin. Rev. Française d’Allergol. 2018, 58, 437–443. [CrossRef]

51. Tang, H.; Zhu, X.; Gong, C.; Liu, H.; Liu, F. Protective effects and mechanisms of omega-3 polyunsaturated fatty acid on intestinal injury and macrophage polarization in peritoneal dialysis rats. Nephrolody 2019, 24, 1081–1089. [CrossRef] [PubMed]

52. Zheng, Z.; Dai, Z.; Cao, Y.; Shen, Q.; Zhang, Y. Docosapentaenoic acid (DPA, 22: 5n-3) ameliorates inflammation in an ulcerative colitis model. Food Funct. 2019, 10, 4199–4209. [CrossRef] [PubMed]

53. Lee, B.; Moon, K.M.; Kim, C.Y. Tight junction in the intestinal epithelium: Its association with diseases and regulation by phytochemicals. J. Immunol. Res. 2018, 2018, 2645465. [CrossRef] [PubMed]

54. Lechuga, S.; Ivanov, A.I. Disruption of the epithelial barrier during intestinal inflammation: Quest for new molecules and mechanisms. Biochim. Biophys. Acta Mol. Cell Res. 2017, 1864, 1183–1194. [CrossRef] [PubMed]

55. Kowalczyk, A.P.; Green, K.J. Structure, function, and regulation of desmosomes. Progr. Mol. Biol. Transl. Sci. 2013, 116, 95–118. [CrossRef]

56. Ulluwishewa, D.; Anderson, R.C.; McNabb, W.C.; Moughan, P.J.; Wells, J.M.; Roy, N.C. Regulation of tight junction permeability by intestinal bacteria and dietary components. J. Nutr. 2011, 141, 769–776. [CrossRef]

57. Cunningham, K.E.; Turner, J.R. Myosin light chain kinase: Pulling the strings of epithelial tight junction function. Ann. N. Y. Acad. Sci. 2012, 1258, 34–42. [CrossRef]

58. Suzuki, T. Regulation of the intestinal barrier by nutrients: The role of tight junctions. Anim. Sci. J. 2020, 91, e13357. [CrossRef]
59. Usami, M.; Muraki, K.; Iwamoto, M.; Ohata, A.; Matsushita, E.; Miki, A. Effect of eicosapentaenoic acid (EPA) on tight junction permeability in intestinal monolayer cells. *Clin. Nutr.* 2001, 20, 351–359. [CrossRef]
60. Usami, M.; Komurasaki, T.; Hanada, A.; Kinoshita, K.; Ohata, A. Effect of gamma-linolenic acid or docosahexaenoic acid on tight junction permeability in intestinal monolayer cells and their mechanism by protein kinase C activation and/or eicosanoid formation. *Nutrition* 2003, 19, 150–156. [CrossRef]
61. Xiao, K.; Liu, C.; Qin, Q.; Zhang, Y.; Wang, X.; Zhang, J.; Liu, Y. EPA and DHA attenuate deoxynivalenol-induced intestinal porcine epithelial cell injury and protect barrier function integrity by inhibiting necroptosis signaling pathway. *FASEB J.* 2020, 34, 2483–2496. [CrossRef] [PubMed]
62. Wang, J.; Zhang, H.; Ma, H.; Lu, B.; Wang, J.; Li, Y.; Li, J. Inhibitory effect of dietary n-3 polyunsaturated fatty acids to intestinal IL-15 expression is associated with reduction of TCRαβ+ CD8α+ CD8β− intestinal intraepithelial lymphocytes. *J. Nutr. Biochem.* 2008, 19, 475–481. [CrossRef] [PubMed]
63. Bentley-Hewitt, K.L.; De Guzman, C.E.; Ansell, J.; Mandimika, T.; Narbad, A.; Lund, E.K. Polyunsaturated fatty acids modify expression of TGF-β in a co-culture model utilising human colorectal cells and human peripheral blood mononuclear cells exposed to *Lactobacillus gasseri*, *Escherichia coli* and *Staphylococcus aureus*. *Eur. J. Lipid Sci. Technol.* 2014, 116, 505–513. [CrossRef] [PubMed]
64. Marion-Letellier, R.; Butler, M.; Dechelotte, P.; Playford, R.J.; Ghosh, S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells-potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. *Am. J. Clin. Nutr.* 2008, 87, 939–948. [PubMed]
65. Wijendran, V.; Brenna, J.T.; Wang, D.H.; Zhu, W.; Meng, D.; Ganguli, K.; Walker, W.A. Long-chain polyunsaturated fatty acids attenuate the IL-1β-induced proinflammatory response in human fetal intestinal epithelial cells. *Ped. Res.* 2015, 78, 626–633. [CrossRef]
66. Zhao, L.; Kwon, M.J.; Huang, S.; Lee, J.Y.; Fukase, K.; Inohara, N.; Hwang, D.H. Differential modulation of Nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells. *J. Biol. Chem.* 2007, 282, 11618–11628. [CrossRef]
67. Vincentini, O.; Quaranta, M.G.; Viora, M.; Agostoni, C.; Silano, M. Docosahexaenoic acid modulates In Vitro the inflammation of celiac disease in intestinal epithelial cells via the inhibition of cPLA(2). *Clin. Nutr.* 2011, 30, 541–546. [CrossRef]
68. Kimura, R.; Takahashi, N.; Lin, S.; Goto, T.; Murotam, K.; Nakata, R.; Kawada, T. DHA attenuates postprandial hyperlipidemia via activating PPAR alpha in intestinal epithelial cells. *J. Lipid Res.* 2013, 54, 3258–3268. [PubMed]
69. Lin, P.W.; Stoll, B.J. Necrotising enterocolitis. *Lancet* 2006, 368, 1271–1283. [CrossRef]
70. Hofmanová, J.; Vaculová, A.; Kozubík, A. Polyunsaturated fatty acids sensitize human colon adenocarcinoma HT-29 cells to death receptor-mediated apoptosis. *Cancer Lett.* 2005, 218, 33–41. [CrossRef]
71. de Vogel-van den Bosch, H.M.; Bünger, M.; de Groot, P.J.; Bosch-Vermeulen, H.; Hooiveld, G.J.; Müller, M. PPARα-mediated effects of dietary lipids on intestinal barrier gene expression. *BMC Genom.* 2008, 9, 231. [PubMed]
72. Jandhyala, S.M.; Talukdar, R.; Subramanyam, C.; Vuyyuru, H.; Sasikala, M.; Nageshwar Reddy, D. Role of the normal gut microbiota. *World J. Gastroenterol.* 2015, 21, 8787–8803. [PubMed]
73. Yu, L.C.-H. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: Exploring a common ground hypothesis. *J. Biomed. Sci.* 2018, 25, 79. [CrossRef] [PubMed]
74. Yu, H.-N.; Zhu, J.; Pan, W.-S.; Shen, S.-R.; Shan, W.-G.; Das, U.N. Effects of fish oil with a high content of n-3 polyunsaturated fatty acids on mouse gut microbiota. *Arch. Med. Res.* 2014, 45, 195–202. [CrossRef] [PubMed]
75. Robertson, R.C.; Seira Oriach, C.; Murphy, K.; Moloney, G.M.; Cryan, J.F.; Dinan, T.G.; Stanton, C. Omega-3 polyunsaturated fatty acids critically regulate behaviour and gut microbiota development in adolescence and adulthood. *Brain Behav. Immun.* 2017, 59, 21–37. [CrossRef]
76. Djuric, Z.; Bassis, C.M.; Plege, M.A.; Sen, A.; Turgeon, D.K.; Herman, K.; Ruffin IV, M.T. Increases in colonic bacterial diversity after w-3 fatty acid supplementation predict decreased colonic prostaglandin E2 concentrations in healthy adults. *J. Nutr.* 2019, 149, 1170–1179. [CrossRef]
77. Coelho, O.G.; Cândido, F.G.; Alfenas, R.D.C.G. Dietary fat and gut microbiota: Mechanisms involved in obesity control. *Crit. Rev. Food Sci. Nutr.* 2019, 59, 3045–3053. [CrossRef]
78. Dourado, E.; Ferro, M.; Sousa Guerreiro, C.; Fonseca, J.E. Diet as a modulator of intestinal microbiota in rheumatoid arthritis. *Nutrients* 2020, 12, 3504. [CrossRef]
79. Ilag, L.L. Are long-chain polyunsaturated fatty acids the link between the immune system and the microbiome towards modulating cancer? *Medicines* 2018, 5, 102. [CrossRef]
80. Costantini, L.; Molinari, R.; Farinon, B.; Merendino, N. Impact of omega-3 fatty acids on the gut microbiota. *Int. J. Mol. Sci.* 2017, 18, 2645. [CrossRef] [PubMed]
81. Shama, S.; Liu, W. Omega-3 fatty acids and gut microbiota: A reciprocal interaction in nonalcoholic fatty liver disease. *Dig. Dis. Sci.* 2020, 65, 906–910. [CrossRef] [PubMed]
82. Costantini, L.; Merendino, N. Polyunsaturated fatty acids and microbiota relationship: Implications in cancer onset and treatment. *J. Clin. Med.* 2020, 9, 3490. [CrossRef] [PubMed]
83. Mozaffari, H.; Daneshzad, E.; Larijani, B.; Bellissimo, N.; Azadbakht, L. Dietary intake of fish, n-3 polyunsaturated fatty acids, and risk of inflammatory bowel disease: A systematic review and meta-analysis of observational studies. *Eur. J. Nutr.* 2019, 59, 1–17. [CrossRef] [PubMed]

84. Calder, P.C. Fatty acids and immune function: Relevance to inflammatory bowel diseases. *Int. Rev. Immunol.* 2009, 28, 506–534. [CrossRef]

85. Marton, L.T.; Goulart, R.A.; Carvalho, A.C.A.; Barbalho, S.M. Omega fatty acids and inflammatory bowel diseases: An overview. *Int. J. Mol. Sci.* 2019, 20, 4851. [CrossRef]

86. MacLean, C.H.; Mojica, W.A.; Morton, S.C.; Pencharz, J.; Garland, R.H.; Tu, W.; Shekelle, P. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and osteoporosis: Summary. In *AHRQ Evidence Report Summaries*; Agency for Healthcare Research and Quality: Rockville, MD, USA, 2004.

87. MacLean, C.H.; Mojica, W.A.; Newberry, S.J.; Pencharz, J.; Garland, R.H.; Tu, W.; Morton, S.C. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. *Am. J. Clin. Nutr.* 2005, 82, 611–619. [CrossRef]

88. Turner, D.; Shah, P.S.; Steinhart, A.H.; Zlotkin, S.; Griffiths, A.M. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses. *Inflamm. Bowel Dis.* 2011, 17, 336–345. [CrossRef]

89. Ajabnoor, S.M.; Thorpe, G.; Abdelhamid, A.; Hooper, L. Long-term effects of increasing omega-3, omega-6 and total polyunsaturated fats on inflammatory bowel disease and markers of inflammation: A systematic review and meta-analysis of randomized controlled trials. *Eur J. Nutr.* 2020, in press. [CrossRef]